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General introduction 
Preface 
The human lung has the largest epithelial surface in the body. This large surface is 
predominantly required to perform its basic function, which is the exchange of 
gases [1]. In order to perform this function, the adult human lung inhales about 
11,000 liters of air every day. Besides normal air, contaminants and different 
microbes (e.g. viruses, bacteria, fungi, parasites and protozoa) may also be 
aspirated into lungs [2]. Luckily, in most cases the innate immune system of lung 
has the ability to clear the inhaled pathogens and noxious particles, and as such 
protects the lungs against diseases and maintains its respiratory function. However, 
when this defense system becomes impaired or even dysfunctional, pulmonary 
diseases may develop [1,3]. These pulmonary diseases can range from acute 
transient to chronic irreversible conditions. 
Although the adoption of hygienic measures and the development of new 
drugs and vaccines have reduced the prevalence, respiratory infections caused by 
different microbes still impose a huge burden on the society in terms of disability, 
mortality and health care services. A significant proportion of these respiratory 
infections are caused by viruses. Usually these infections are benign in nature, but 
in patients with chronic respiratory conditions with a concomitant impaired (local) 
immune system they could become life threatening. For example, asthma and 
chronic obstructive pulmonary disease (COPD) are the two chronic respiratory 
conditions where viral infections are the most important cause of exacerbations, 
acute worsening of the symptoms, which could even lead to mortality. Thus, 
prevention of these respiratory infections in asthma and COPD is the need of the 
hour.       
1.0 Acute respiratory tract infections 
Acute respiratory tract infections (ARIs) are the most frequently encountered 
clinical syndrome for people to present for medical care and are still a matter of 
concern even in developed countries [2]. Among all classes of microorganisms 
which can infect the respiratory tract, bacteria and viruses are the most common 
infectious agents to cause ARIs. Conventionally, and depending on the anatomical 
region involved, ARIs are divided into two groups: acute upper respiratory tract 
infections (URTIs) and acute lower respiratory tract infections (LRTIs) [4]. 
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1.1 Upper Respiratory Tract Infections  
The upper respiratory tract includes the nose, sinuses, larynx and pharynx which 
are collectively called upper airways [5]. Infections associated with this part are 
common cold, rhinitis, influenza, laryngitis, sinusitis, pharyngitis, tonsillitis and 
otitis media. These infections are caused by different viruses and bacteria and are 
the major cause of illness, especially in children and older people [6-8]. Among 
ARIs, acute URTIs are the predominant reason to seek medical care. In United 
States alone, uncomplicated acute URTIs are responsible for 25 million visits to 
family physicians and about 20 million days of absence from work or school each 
year [9]. Fortunately, most URTIs are generally not life threatening [10]. They are 
usually mild, mainly caused by viruses and their symptoms resolve within three to 
ten days. A typical example of such an infection is a common cold, a very common 
benign and self-limiting disease [9,10]. Despite the fact that more than 200 
different types of viruses and some bacteria can cause a common cold, human 
rhinovirus (HRV) are responsible for the majority of these cases [9,11-14]. Other 
viruses frequently implicated are coronaviruses, para-influenza virus (PIVs), 
respiratory syncytial virus (RSV) and adenoviruses [9,15]. Another highly contagious 
infection of the upper respiratory tract is seasonal influenza. Type-A, -B and –C 
influenza viruses are the causative agents and it can lead to significant morbidity 
and mortality, in particular among children less than two years of age or in people 
older than 65. Otherwise, usually patients recover within a week (World Health 
Organization. Influenza Seasonal 2009, http://www.who.int/mediacentre/ 
factsheets/fs211/en/index.html) [16,17]. Sinusitis and otitis media are two other 
important acute URTIs, which are caused by both viruses and bacteria. Also for 
these diseases, like common cold, rhinoviruses are mainly involved in the induction 
of these infections and the bacteria which are commonly implicated are 
Streptococcus pneumonia (S. pneumonia), Haemophilus influenza (H. influenzae) 
and Moraxella catarrhalis (M. catarrhalis) [18-22].  
1.2 Lower Respiratory Tract Infections 
The lower respiratory tract extends from the trachea through the branching 
bronchi to the terminal alveoli [23]. Acute infections, which encompass this part, 
are mainly responsible for acute bronchitis, acute exacerbations of chronic 
bronchitis and pneumonia. In outpatient settings, these are the most frequently 
diagnosed infections [24]. In contrast to URTIs, which are mainly responsible for 
morbidity, LRTIs are also associated with significant mortality and are the third 
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leading cause of death all over the world (WHO 2008 updated 2011 
http://www.who.int/mediacentre/factsheets/fs310/en/index.html). Although 
bacterial agents can also cause these LRTI, the majority of the cases are attributed 
to respiratory viruses, and in particular to influenza viruses [25]. Among these 
LRTIs, acute bronchitis is usually mild and self-limiting [26,27]. On the other hand, 
pneumonia is the most frequent reason of death of children in developing 
countries and of elderly in developed countries [28]. It is estimated that every year 
1.2 million children under the age of five die due to pneumonia. The first and 
second most common causes of pneumonia in children are S. pneumoniae and H. 
influenza respectively. Among viruses, RSV is the major cause. (WHO 2012, 
http://www.who.int/mediacentre/factsheets/fs331/en/). S. pneumoniae and H. 
influenza are also the major cause of community acquired pneumonia (CAP) in 
adults. Other important bacteria associated with CAP are Legionella species and 
Chlamydia pneumonia (C. pneumonia)[29,30]. Among viruses, influenza viruses are 
the major cause of CAP in adults [31]. Other viruses which are frequently detected 
during lower ARIs in children and CAP in adults are PIVs, adenovirus and HRV 
[28,32].  
2.0 Pulmonary immune systems 
Because of its anatomical nature, the epithelial surface of the lungs is permanently 
exposed to a variety of inhaled substances like environmental pollutants, cigarette 
smoke, pathogens or airborne allergens. In order to protect the lungs from these 
noxious agents and to maintain its proper functioning, complex defense systems 
have evolved over time. These defense mechanisms can be divided into the innate 
immune system, which provides immediate protection in a nonspecific manner, 
and the adaptive or acquired immune system, which provides late protection in a 
more specific manner. Nevertheless, both systems work in close concert to 
preserve proper functioning of the lungs. Both systems will be discussed in detail in 
the next paragraphs and a schematic overview is presented in figure 1.  
2.1 Innate/Nonspecific defense system 
As part of the non-specific defense system, immediate protection is provided by 
physical barriers. Among these, first are the anatomical barriers. Depending on the 
size of the inhaled particles, these barriers block their penetration into the lungs at 
different locations. Particles of more than 30 µm are filtered by nasal hair 
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(vibrissae). Those with a size between 10-30 µm are mostly captured in the nasal 
airways, turbinates and nasal septum [3,33]. Further downstream, where the large 
airways start branching, airflow is reduced and here most of the particles, having 
sizes of more than 2 µm, sediment due to gravity [34,35]. Thus, the particles which 
reach the alveoli are mostly less than 2 µm of size.  
The next barrier is the airway epithelium. Epithelial cells are attached to 
their neighbors by intercellular tight junctions, adherins junctions, gap junctions 
and desmosomes. As a result cells are separated into a basolateral and luminal side 
and thereby provide an impermeable barrier for microbes [36,37]. Apart from its 
function as a barrier, from trachea down to the bronchioles the airway epithelium 
is lined with airway surface liquid (ASL). ASL is composed of the outer mucous 
blanket and the inner low viscosity periciliary sol. About 90% of the particles and 
microbes which enter and precipitate into the airways are entrapped in the mucous 
blanket [38,39]. Then, due to coordinated movements of cilia present on epithelial 
cells, mucous is propelled towards the oral cavity, where it is either expectorated 
or swallowed [3,33]. Other reflexes like sneezing and coughing also help to remove 
mucous along with unwanted substances [34]. ASL not only helps to entrap and 
remove the foreign particles, it also contains different antimicrobial molecules. 
Examples of these molecules include lactoferrins, lysozyme, secretory leukocytes 
protease inhibitor, defensins and cathelicidins [40]. Altogether these molecules 
collaborate to inhibit microbial growth and ultimately kill the microbes. 
However, if pathogens evade these defense systems, they finally 
encounter host cell membranes. Host immune cells recognize these pathogens by 
pattern recognition receptors (PRRs). PRRs have the ability to detect conserved 
molecular patterns; the so-called pathogen associated molecular patterns (PAMPs) 
present on the microorganisms [3]. Toll-like receptors (TLRs), type I trans-
membrane receptors, constitute the major family of PRRs. Until today, 10 
functional TLRs in human and 12 in mouse have been identified [41]. TLR1, 2, 4, 5 
and 6 are localized on the cell surface and largely recognize microbial membrane 
components [41,42]. Alternatively, other TLRs (TLR3, 7, 8 and 9) are expressed in 
the intracellular vesicles and are responsible for the detection of nucleic acids, 
mainly viral nucleic acids [41,43]. TLR3 recognize double stranded RNA (dsRNA), 
TLR 7 and 8 recognize single stranded RNA (ssRNA) and TLR9 recognize CpG DNA 
[44].    
Upon recognition of ligands (PAMPs) by PRRs intracellular signaling starts 
which leads to a change in the expression of many different genes. This ultimately 
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leads to the production of different cytokines and chemokines, which regulate the 
inflammatory and immune responses [34]. Besides leukocytes, epithelial cells, 
which also express most of the TLRs, play an important role in this context. They 
also express intracellular virus recognition receptors like retinoic acid-inducible 
gene 1 (RIG-1) and melanoma differentiation associated gene 5 (MDA-5). Similar to 
TLR3, 7, 8 and 9, RIG-1 and MDA-5 are the important sensors of viral RNA and play 
central role in the detection of viral infections [44]. Thus after activation of these 
receptors, cells start producing different cytokines, chemokines and other immune 
mediators which not only activate and recruit other immune cells to the site of 
infection, but also kill the pathogens [3,36,39]. Among these cytokines, interferons 
(IFNs), produced in direct response to viral infection, are central to the cellular 
defense against viral infections. Their role will be discussed in detail in the section 
“2.3 Antiviral defense”.      
Among the pulmonary innate immune cells, alveolar macrophages are the 
most prominent ones. They constitute about 95% of the airspace leukocytes. 
Lymphocytes comprise ~1-4% of the total immune cell population and only about 
1% are neutrophils [45]. Resident tissue macrophages are the most important 
phagocytic cells. In response to infection or injury, they ingest all the inhaled 
pathogens and other particulate matter or debris. They also produce different 
cytokines and chemokines which recruit other immune cells [45,46].  
Also present in the lungs are dendritic cells. As compared to macrophages, 
which are poor antigen presenting cells, dendritic cells (DCs) are specialized for this 
job. After ingestion, DCs process the antigen and present it to the lymphocytes and 
thus initiate the adaptive immune response.  
Although under normal conditions only present in low amounts, following 
infection neutrophils are massively recruited to the lungs in response to IL-8 and 
CXC chemokines, produced by macrophages and epithelial cells. Their main 
function is to phagocytose and kill the invading pathogen [46-48]. Mast cells are yet 
another important cell type which play an important role in the respiratory 
immune system. Along with the expression of different TLRs, they also express the 
receptor for IgE. Activation of mast cells upon binding of ligands to their receptors 
result in the production of different molecules that stimulate inflammation and can 
also polarize T-cells [46]. 
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2.2 Acquired/specific defense system 
The next line of defense after the non-specific/innate system is the 
adaptive/acquired defense system, which is directed against specific pathogens or 
molecules. For the initiation of this system, dendritic cells (DCs) play a central role. 
Two phenotypes of pulmonary DCs have been identified: conventional DCs 
(cDCs)/myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) [49]. In lungs, immature 
cDCs are found in close contact with the epithelium starting from the nose down to 
the alveoli [50-52]. They form a tight network throughout the mucosa and in the 
alveoli and send their extended dendritic projections through the epithelial tight 
junctions into the airway lumen. Here they detect and take up the foreign antigens 
[53,54]. For this cDCs are equipped with a number of different receptors including 
TLRs [55]. With the help of these receptors they recognize and capture the antigens 
followed by a maturation process. During this process the expression of various 
chemokine receptors (CCR1, 2, 5 and 6) is down-regulated while the expression of 
CCR7 is up-regulated which drives migration of DCs to lymph nodes [56,57]. In the 
lymph nodes, DCs further mature into antigen presenting cells. Antigens are 
processed by two different pathways. In the endocytic pathway, antigens obtained 
from extracellular space are processed into small peptides. These peptides are then 
loaded on major histocompatibility complex (MHC) class II molecules. Alternatively, 
in the endogenous or classical pathway, intracellular antigenic peptides are 
processed and loaded onto MHC class I molecules. These antigen loaded MHC class 
I and II molecules are then recognized by CD8
+
 and CD4
+
 T-cells, respectively, which 
along with other co-stimulatory molecules leads to T cell stimulation, proliferation 
and activation. As a result of this, naive T-cells are activated and polarized into 
antigen specific T-effector phenotype [58-61]. Polarized and activated subsets of 
CD4
+
 T-cells are T-helper 1 (Th1) and T-helper 2 (Th2) cells which constitute Th1 
and Th2 responses respectively. Th1 response is characterized by the production of 
interferon gamma (IFNγ), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) 
and granulocyte/macrophage colony-stimulating factor (GMCF) by Th1 cells. This 
response activates the alveolar macrophages to kill the intracellular pathogens.  
Also in the presence of Th1 cytokines, the interaction between DCs, Th1 cells and 
CD8
+
 T cells leads to the development of cytotoxic T-lymphocytes (CTL). These CTLs 
not only activate the macrophages but they also kill the infected cells themselves. 
On the other hand, production of IL-4, IL-5, IL-10 and IL-13 characterizes the Th2 
response. These cytokines have anti-inflammatory properties and play an 
important role in tissue eosinophilia and antibody production [62,63].  
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Another type of T-cells is the regulatory T-cell (Treg). Treg cells express 
transcription factor forkhead box P3 (Foxp3) and most of them are CD4
+
 T cells 
which also express IL-2 receptor-α chain (CD25). They naturally develop in the 
thymus but can also be induced in peripheral tissues. These cells control the 
immune responses by suppressing the effector function of different immune cells. 
Moreover, they suppress their activation and proliferation (CD4
+
, CD8
+
 T cells, 
antigen presenting cells, B cells etc.) thereby dampening the immune response 
which prevents tissue damage because of an exaggerated inflammatory reaction 
[64]. In contrast to cDCs, pDCs are poor antigen presenting cells. Also cDCs and pDC 
differ in their expression of TLRs. TLR7 and TLR9 are strongly expressed by pDCs 
while TLR2/3/4/5 are not expressed by pDCs. Due to this differential expression of 
TLRs, cDCs recognize bacterial products more efficiently while pDCs are 
predominantly equipped for the recognition of viral RNA/DNA and methylated DNA 
(CpG motifs). Upon viral infection pDCs produce large amounts of type-1 
interferons, which induce a strong antiviral response and limit the viral replication. 
Also they migrate to lymph nodes where they promote the Th1 response by 
secreting Type-1 interferons [55,65].  
2.3 Antiviral defense 
As discussed above, a large proportion of upper and lower respiratory tract 
infections are caused by viruses. To fight against viral infections, cells are equipped 
with different PRRs which immediately detect viral PAMPs and activate antiviral 
defense mechanisms. Detection of viral PAMPs via different PRRs results in the 
activation of different antiviral signaling pathways which culminate in the 
downstream activation of common transcription factors like interferon regulatory 
factor 3 (IRF3), nuclear factor kappa B (NFκB) and activator protein 1 (AP1) [66]. 
Activated transcription factors are then translocated to the nucleus where they 
start the transcription of IFN genes, which finally leads to the production and 
release of IFNs by cells [66,67]. Three different types of IFNs have been identified 
so far: type-I IFNs (IFNα/β), type-II IFN (IFN-γ) and type-III IFNs (IFN-λ1, -λ2 and –
λ3). Although all three types have antiviral properties, type-I and type-III are the 
IFNs which are predominantly produced in direct response to viral infections 
[68,69]. Once released type-I and type-III IFNs then bind to their specific receptors 
in an auto- or paracrine fashion, thereby activating intracellular signaling pathways 
which leads to the transcriptional induction of interferon stimulated genes (ISGs) 
[67,70]. Proteins encoded by these ISGs finally exert the antiviral effects through 
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different mechanisms including interference with translation, degradation of RNA 
and interference with virus assembly and release [67]. Intriguingly, and in contrast 
to the type I IFNs, not all cell types respond to type-III IFNs. The main reason for 
this difference is that expression of receptors for type-III IFNs is limited to few 
types of cells (predominantly epithelial cells)in contrast to the ubiquitous 
expression of receptors for type-I IFNs [66,67,71]. Because of this cell type specific 
expression, it has been suggested that type-III IFN might be better suited for 
treatment of viral infections e.g. of the respiratory tract. However, clinical data are 
lacking and experimental data are scarce. 
 
 
Figure-1. Schematic representation of defense system of healthy airways: Airway epithelium is the first 
line of defense against foreign insults. Layer of epithelial cells connected with tight junctions act as a 
barrier. Secreted mucus layer not only trap the foreign particles but also contain different antimicrobial 
peptides which kill the microorganisms. In response to foreign insults, epithelial cells produce cytokines, 
chemokines and other important immune mediators which not only produce direct lethal effects on 
microorgamisms but also recruit other immune cells and activate the adaptive immune system.   
 
Along with their direct antiviral properties, both type-I and type-III IFNs 
also have immunodulating properties [44,68,72]. Although the immunoregulatory 
properties of type-III IFNs are less extensively studied as compared to type-I IFNs, 
overlap between the two has been observed. For example both type-I and type-III 
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IFNs increase natural killer cells and T cell toxicity [73,74], both promote Th1 
responses [74,75], both upregulate the MHC class I molecules expression [76-78] 
and both mediate cell apoptosis [79-81]. On the other hand type-II IFN-γ is produce 
mainly by mitogen activated natural killer, natural killer T cells and by Th1 cells [82] 
and plays important roles e.g. in innate immune response against intracellular 
infections and the regulation of adaptive immune response [83].   
3.0 Chronic respiratory diseases 
Among chronic diseases, those affecting the respiratory tract are the third leading 
cause of death [84]. Over one billion people suffer from chronic respiratory 
diseases (CRD) and more than half of them live in low and middle income countries 
[85]. Every year, more than 4 million people die from CRDs [86]. Among the most 
prevalent CRDs are chronic obstructive pulmonary disease (COPD) and asthma. 
Another important genetic disorder, in which chronic infections and ongoing 
inflammation are commonly seen, is cystic fibrosis (CF) [87].  
Defense systems of healthy lungs usually resolve infections efficiently and 
preserve the normal lung functioning. However, in the presence of CRDs 
respiratory infections occur more with more severity. Apart from other 
mechanisms which can account for increased severity, it has also been 
demonstrated that respiratory defense systems in CRDs may not function properly 
[88-91]. Infections then can lead to an acute worsening of the symptoms called 
acute exacerbations (AE). Management of AEs is the major problem in CRDs. AEs 
not only accelerate the progression of the disease but are also the major cause of 
decline in lung function, morbidity and mortality in CRDs. Because of the enormous 
impact of exacerbations, not only on patients but on the community in general, 
prevention of exacerbations in above mentioned CRDs is a major goal of current 
scientific research. The role of respiratory infections and immune modulation in the 
induction of exacerbations will be discussed in the following sections. 
3.1 Chronic obstructive pulmonary disease  
COPD, which is characterized by irreversible airflow obstructions, is the most 
common chronic respiratory condition in adults [92]. Worldwide, more than 200 
million people are affected. COPD is the fourth leading cause of death and its 
prevalence is expected to increase further [93-95]. Different mechanisms have 
been implicated in the development of disease. Among these, tobacco smoking is 
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considered to be the primary underlying risk factor for the disease. Burning of 
biomass fuels, which is a major source of indoor pollution in developing countries, 
is also associated with the development of the disease [96]. Yet, susceptibility to 
the disease varies between individuals. Though it also depends on the amount and 
duration of smoking, not all smokers develop the disease. This suggests that 
genetic factors might also be involved. [97]. Genetic defects resulting in deficiency 
of α1-antitrypsin (inhibitor of neutrophil elastase) and ultimately the development 
of emphysema have also been identified as important causes of the disease. Also, 
oxidative stress and imbalance between proteinases and anti-proteinases results in 
increased airway inflammation [98-100]. Moreover, age-related changes and 
autoimmunity have been proposed in the progressive course of the disease 
[101,102]. Importantly, the central aspect within all these mechanisms is the 
exaggerated chronic inflammation mostly likely in combination with host genetic 
susceptibility. 
In the management of COPD, AEs are the major problem and are 
associated with significant morbidity and mortality. It has been shown that AEs are 
a strong predictor of subsequent mortality in COPD patients, especially in patients 
who suffer from three to four exacerbations in a year with hospitalization 
[103,104]. In addition, AEs also significantly increase the economic burden due to 
extra healthcare visits, treatments and hospitalizations [105].  
Although different factors are associated with the induction of AEs in 
COPD, respiratory infections caused by bacteria and viruses, are implicated in the 
majority of these AEs. [106,107]. About 50% of these AEs are attributed to bacterial 
infections and the most frequently isolated bacterial species is H. influenzae. Other 
commonly isolated species include M. catarrhalis, S. pneumoniae, and also 
Pseudomonas aeruginosa (P. aeruginosa) [108]. Moreover, the lower respiratory 
tract of COPD patients is frequently colonized by bacteria. An association between 
bacterial load and induction of AEs has been proposed, although there are 
significant discrepancies between reports [106,109-112]. On the other hand, 
acquisition of new bacterial strains has been strongly associated with the induction 
of AEs in COPD. However, along with the pathogenic ability of newly acquired 
strains, modulation of immune mechanisms also plays an important role in the 
pathogenesis of AEs [108,113,114].   
The relative contribution of viruses in the induction of COPD AEs is still 
debated. Earlier, due to lack of sensitive diagnostic tools, only 10-20% of COPD AEs 
were associated with viral infections. Nevertheless, due to the development of 
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more sensitive PCR-based diagnostic tools, rate of detection of viruses in COPD AEs 
has been increased significantly. As a result of this up to 60% of COPD AEs have 
been reported to be virus-induced [106-108,110,115].  In these virus-induced AEs 
human rhinoviruses (HRVs) are most commonly isolated. Other frequently isolated 
viruses are (para-)influenza viruses, respiratory syncytial virus (RSV), corona 
viruses, adenovirus and human metapneumovirus [116]. Apart from just the 
detection of viruses in COPD AEs, a direct correlation between viral infection and 
development of symptoms of AEs has also been shown. In an experimental HRV 
infection study in COPD patients, Mallia and colleagues observed the development 
of typical lower respiratory symptoms of AE. This strongly suggests that viral 
infections have a causative role in the induction of AEs [117].   
Apart from the fact that both viral and bacterial agents can independently 
induce AEs, virus-bacterial co-infections have also been linked to the induction of 
COPD AEs [109]. Notably infection with either a virus or a bacterium can facilitate 
the subsequent infection with the other microbe [118,119]. These AEs induced by 
co-infections are usually more severe and often result in longer hospital stays 
[106,109].  
3.2 Impairment of immune system in COPD 
In COPD, different abnormalities in the respiratory immune mechanisms have been 
reported which enhance the susceptibility to infections [92,108]. Cigarette 
smoking, which is the major risk factor for the development of disease, has 
deleterious effects on the defense system of lungs [120]. Smoking leads to 
excessive production and impaired clearance of mucus. This happens because of 
mucous cell hyperplasia, replacement of differentiated ciliated cells and secretory 
cells with squamous cells [121-123]. These effects are accompanied with loss of 
Clara cells, resulting in lower production of host defense factors like surfactant 
proteins [124]. Furthermore, cigarette smoke increases the permeability of 
epithelium and impairs the junction barrier formation through down-regulation of 
a broad transcriptional program and thereby impairing the antimicrobial defense in 
COPD smokers [125-127]. 
The function of important airway immune cells like alveolar macrophages 
(AM), DCs, neutrophils and natural killer cells seems impaired in COPD. In smokers 
and COPD patients the number of AM and neutrophils is augmented. Increased 
numbers of AMs is correlated with the airway obstruction and severity of disease 
[128]. Alternatively in COPD smokers, impaired functioning of AMs seems to play 
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an important role in suppression of host defense. For example, reduced phagocytic 
activity, inactivation of M1 polarization and activation of subtypes of M2 
polarization and suppression of innate immune genes like CXCL9, CXCL11, CCL5 
have been observed in COPD [89,129]. Due to suppressed M1 polarization, The 
numbers of IFN-γ producing T cells are reduced whereas the amount of CD4+CD25+ 
regulatory T cells is increased which could maintain the immunosuppressive 
environment [130,131]. Similarly, neutrophil-derived elastase could lead to 
emphysematous destruction of lung tissue [132]. Furthermore, although 
neutrophils from COPD patients migrate faster, their accuracy seems impaired 
suggesting that they may have become more harmful than beneficial [133]. On the 
other hand, the number of mature DCs is significantly reduced in COPD, while 
marked depression in activity of NK cells has been observed in smokers and COPD 
smokers [134-137]. 
Previously it has been suggested that cigarette smoking in particular 
enhances the susceptibility to viral infections of respiratory tract [138,139]. In vitro 
studies have shown that cigarette smoke not only impairs the production of IFNs 
but also affects intracellular signaling induced by IFNs [140,141]. Similarly, ex vivo 
rhinovirus infection of cells, derived by bronchoalveolar lavage from COPD patients, 
showed deficient induction of IFN-β, IFN-α and IFN-λ [117]. Moreover, when COPD 
mice were infected with rhinovirus they also showed deficient production of IFN-α, 
-β and –γ as compared to controls [142]. In contrast, infection of epithelial cells 
from COPD and controls with HRV showed no difference in interferon production. 
Yet, higher viral loads and increased production of inflammatory mediators was 
observed in cells from COPD patients than controls, indicating that antiviral 
defense in COPD patients is compromised [143].    
3.3 Asthma 
Asthma is a chronic respiratory condition of airways, which is characterized by 
airway hyper-responsiveness (AHR) and reversible airflow obstruction [144,145]. 
Worldwide, about 300 million people are estimated to have asthma and the 
incidence is expected to increase further in coming years. Every year, about 
250,000 deaths are attributed to asthma. Also, it accounts for 1% of the total global 
disease burden (Global Initiative for asthma (GINA) Global strategy for asthma 
management and prevention (updated 2012, www.ginasthma.org). Asthma AEs, 
like in COPD, inflict a significant social and economic burden. Costs of treating 
asthma patients with AEs have been shown to be three and half times higher than 
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treating patients without AEs [146]. Even for patients who do not require hospital 
admissions, significant costs are still incurred just because of visits to the hospital 
emergency departments [147].  
Risk factors for the development of asthma involve complex interaction of 
host and heterogeneous environmental factors. Among the host factors, the most 
important ones are genetic factors. Asthma is a complex heritable disorder and 
many candidate genes have been identified which can influence the development 
of asthma [148,149]. Obesity and sex are the other host-related factors. Obesity 
increases the susceptibility for the development of asthma. Similarly, the 
prevalence of asthma is more in males than in females during childhood, while 
among adults females are at a higher risk than males. [150-153]. Different 
environmental factors can contribute to the development of asthma. Particularly, 
in children risk factors are persistent sensitization to allergens [154,155], viral 
infections [156,157], bacterial colonization [158], prenatal and post-natal smoking 
and exposure to other pollutants in early childhood [159,160]. Factors associated 
with inception of asthma in adults are less clear as compared to childhood-onset 
asthma. Yet, asthma related to irritant exposure in the work place, which is called 
occupational asthma, is more frequently observed in adults. Other factors could be 
cigarette smoking, upper airway diseases, paracetamol and aspirin intake and 
respiratory infections [161]. 
Similar to COPD, main triggers of AEs in asthma are respiratory infections. 
However, in contrast to COPD, where both bacterial and viral infections have more 
or less equal share in the induction of AEs, asthma AEs are mainly associated with 
viral infections. Along with a strong involvement of viruses in the development of 
asthma, they are also detected in approximately 80-85% of AEs in children and in 
more than 60% of AEs in adults [162-164]. Most commonly isolated viruses are 
rhinoviruses which account for about two-third of virus-induced asthma AEs. 
Seasonal patterns of occurrence of AEs, which peak during fall and spring especially 
in children, correspond to the pattern of HRVs isolation. This suggests a causal 
relationship between HRV infections and the induction of AEs [165-167]. Other 
viruses, which have been detected during asthma AEs, are RSV, (para-)influenza 
viruses, coronaviruses, human metapneumoviruses, adenoviruses and bocaviruses 
[168]. Yet, in children of 2-17 years of age, only HRVs were found to be significantly 
associated with asthma AEs [169]. Although different studies suggest a strong 
relationship between viral infection (in particular HRV) and induction of AEs, other 
studies also indicate the involvement of multiple factors [170,171]. Allergy and 
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environmental pollution are the major other factors. Allergy, allergen exposure, 
pollutants and virus infection have been shown to synergistically increase the risk 
of induction of AEs both in children and in adults [172-174].  
The role of bacterial infections in the induction of exacerbations in asthma 
is not clear. Possible relationship between the colonization of bacterial species like 
S. pneumoniae, H. influenzae, M. catarrhalis and development of asthma has been 
shown by Bisgaard and colleagues [158]. In another study, the same group has also 
shown an association between infections by these bacteria and acute wheezing in 
children [175]. Yet, these studies do not prove the causal role of these bacterial 
species in the induction of exacerbations. Similarly, infections with atypical 
bacterial species have also been suggested to play a role in the pathogenesis of 
asthma and in the induction of exacerbations: however, until now data are still 
inconclusive. Cunningham and colleagues reported increased levels of C. 
pneumoniae specific IgA antibodies in children who had four or more exacerbations 
as compared those who had just one [176]. In another study Wark and colleagues 
reported  that among patients of AEs of asthma, 47% had antibodies against C. 
pneumoniae and 38% had increased levels C. pneumoniae antibodies [177]. 
Nonetheless, in both of these studies detection levels of viruses were also very 
high. For this reason infections with C. pneumoniae have been suggested to 
contribute to the virus-induced asthma exacerbations rather than being an 
independent inducer [178]. Still, another study showed significant improvement in 
AEs symptoms and lung function following treatment with telithromycin, an 
antibiotic specifically active against atypical bacteria, [179]. This indicates the 
possible involvement of atypical bacteria in the induction of asthma AEs. However 
further studies are required to explore the role of bacterial infections in the 
induction of asthma exacerbations.   
3.4 Impairment of immune system in asthma 
The immune system of asthmatics is perturbed at different levels and may as such 
contribute to disease progression. For example, the barrier function of the 
epithelium, which is the first point of contact with foreign particles, is intrinsically 
defective in asthmatics. [180]. As a result, penetration of inhaled pathogens into 
the airway tissue is facilitated. This barrier is also disrupted by other insults, which 
are implicated in the pathogenesis of asthma, like proteolytic allergens, viruses and 
air pollutants (for instance, environmental particulates and tobacco smoke) 
[181,182]. Infection of epithelial cells with viruses can also lead to loss of cilia and 
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impairment of mucocilliary clearance. However, these effects could be secondary 
to the release of pro-inflammatory cytokines by damaged cells [168].  
Also the antiviral response in asthmatics is impaired. This was indicated for 
the first time when Corne and colleagues showed that viral infections induced 
more severe and prolonged symptoms in asthmatics as compared to non-
asthmatics [171]. Later studies suggested that the underlying mechanism could be 
an impaired interferon response to viral infections in asthmatics. In a seminal 
study, Wark and colleagues showed that in response to HRV infection bronchial 
epithelial cells from asthmatics produce less IFN-β than cells from non-asthmatics 
[183]. In line with this, Contoli and colleagues also observed decreased production 
of type-III IFN-λ, when bronchoalveolar lavage cells from asthmatics were infected 
with HRV. They also found that levels of IFN-λ were negatively correlated with 
asthma symptoms and viral load [184]. Further insight was provided by Bullens and 
colleagues, who showed that IFN-λ1 mRNA levels were negatively correlated with 
asthma symptoms [185]. These studies show impairment of the antiviral response 
in asthmatics and importance of interferons in antiviral defense. Yet, the precise 
underlying mechanisms responsible for the impaired interferon response following 
viral infections in asthmatics are still unknown. 
Normal functioning of some of the immune cells may also be disturbed in 
asthma. Oliver and colleagues demonstrated that HRV impairs antibacterial 
defense of alveolar macrophages [186]. Similarly after experimental HRV infection, 
prolonged infiltration of eosinophils was observed in asthmatics as compared to 
healthy subjects [187]. However, whether this prolonged infiltration is beneficial or 
destructive is not clear [188].  
In contrast to healthy subjects, interleukin-8 (IL-8) levels in nasal lavages 
from asthmatics are significantly increased after HRV infection and increased IL-8 
levels are correlated with airway hyperresponsiveness [189,190]. This suggests that 
HRV infection in asthmatics can increase the neutrophilic inflammation which may 
then lead to exacerbation. 
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Aims and outline of the thesis 
Acute exacerbations in both asthma and COPD negatively affect the quality of life 
of patients. They not only deteriorate the lung function but they are also major 
contributors to morbidity and mortality. Unfortunately, currently available 
strategies and therapies for the prevention and treatment of AEs have limited 
efficacy. Thus, studies focusing on the exploration of new possibilities to treat or 
prevent AEs are urgently needed. Along with this, the identification and a better 
understanding of the factors, which play important roles in the induction of 
exacerbations by some of the most common triggers, could also help to formulate 
new strategies to prevent AEs.  
Among these triggers for AEs in asthma and COPD, viral infections are 
currently considered as the most important ones. Moreover, antiviral responses in 
asthmatics and COPD patients seem to be impaired. Alternatively, apart from direct 
cytopathological effects of viral infections, also an exaggeration of the 
inflammatory response, which is a core feature in CRDs, by viral infections could 
also lead to AEs. Thus prevention of viral infections as well as excessive 
inflammation could significantly reduce the frequency of AEs. Because of their 
potent antiviral characteristics prophylactic treatment with exogenous interferons 
could be one possible therapeutic option. Moreover, anti-inflammatory 
characteristics have been attributed to IFNs which may also be beneficial to 
prevent AE. In the present thesis we tested the hypothesis that prophylactic 
treatment with exogenous IFNs is a valuable option to prevent viral infections 
and excessive inflammation of the respiratory tract. To examine this hypothesis, 
different in vitro studies were conducted to determine the antiviral and anti-
inflammatory effects of administration of exogenous interferons to airway 
epithelial cells.     
Previously we have shown that IFN-β, a member of the type-I interferon 
family, provides long lasting protection against viral infections in airway epithelial 
cells. IFN-λ1, on the other hand, is a member of newly discovered type-III 
interferon family, which are speculated to be more important for the respiratory 
tract than type-I interferons. In chapter 2, we examined the hypothesis that 
prophylactic administration of exogenous IFN-λ1 is equally or even more effective 
than IFN-β in protecting epithelial cells against subsequent rhinovirus infections.  
Inflammation is an important feature in AEs and can be induced by 
different exogenous triggers. These triggers might act through different 
mechanisms to induce inflammation but it can finally lead to the induction of AEs. 
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Therefore, prevention of inflammation might be a useful strategy to avoid acute 
exacerbations in chronic respiratory patients. Interestingly, besides antiviral 
characteristics also anti-inflammatory properties have been attributed to IFN-β. 
However, the effects of IFN-λ on inflammation have been studied less extensively. 
In chapter 3 we evaluated the hypothesis that, next to anti-viral properties, both 
IFN-β and IFN-λ have anti-inflammatory features. To study this hypothesis, the 
inflammatory response of (infected) macrophages and epithelial cells, both in 
mono and co-cultures, upon administration of exogenous interferons was 
investigated.              
Majority of the patients with chronic respiratory diseases, and in particular 
COPD, are either current smokers or ex-smokers. Previously, it has been 
demonstrated that cigarette smoke impairs the pulmonary immune system. 
However, it is unclear whether cigarette smoke also has a negative effect on the 
capacity of exogenous interferons to provide protection against viral infections in 
epithelial cells thereby limiting its potential clinical applicability. Thus in chapter 4 
we evaluated the ability of exogenous interferon to provide protection against viral 
infection in epithelial cells which were first treated with cigarette smoke extracts. 
Among viruses, HRVs are the major inducers of exacerbations and about 
90% of the known HRVs are part of the major group HRV family. Major group HRVs 
use the intercellular adhesion molecule-1 (ICAM1) as their receptor for attachment 
to the cells. Previously, H. influenzae, which is commonly isolated from COPD 
patients, has been shown to up-regulate the ICAM1 expression on epithelial cells 
leading to increased binding of HRV to the cells. Although this indicates that H. 
influenzae might assist HRV to establish the infection definite proof for is still 
lacking. In chapter 5, we evaluated the hypothesis that H. influenzae treatment 
enhances the replication of virus and also the inflammatory response upon 
subsequent infection. Apart from the effects of H. influenzae on major group HRV 
infections, we also tested the effects on minor group HRV infections (which use the 
LRL-receptor for adherence to cells) and the unrelated RSV to determine whether 
effects of H. influenzae are specific for major group HRV or induce a more general 
effect in bronchial epithelial cells. 
In the last chapter of the thesis, chapter 6 findings are summarized and 
discussed.         
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Abstract 
Background 
Impaired interferon (IFN) production has been observed in various obstructive 
respiratory diseases. This contributes to enhanced sensitivity towards viral 
infections triggering acute exacerbations. To compensate for this impaired host IFN 
response, there is need to explore new therapeutic strategies, like exogenous 
administration of IFNs as prophylactic treatment. In the present study, we 
examined the protective potential of IFN-λ1 and compared it with the previously 
established protecting effect of IFN-β. 
Methods 
A549 cells and human primary bronchial epithelial cells were first treated with 
either IFN-β (500 IU/ml) or IFN-λ1 (500 ng/ml) for 18h. For infection, two 
approaches were adopted: i) Continuous scenario: after pre-treatment, cells were 
infected immediately for 24h with human rhinovirus 1B (HRV1B) in IFN-containing 
medium, or were cultured for another 72h in IFN-containing medium, and then 
infected for 24h with HRV1B, ii) Pre-treatment scenario: IFN-containing medium 
was replaced after 18h and cells were infected for 4h either immediately after pre-
treatment or after additional culturing for 72h in IFN-free medium. The protective 
effect was evaluated in terms of reduction in the number of viral copies/infectious 
progeny, and enhanced expression of IFN-stimulated genes (ISGs). 
Results 
In both cell types and in both approaches IFN-λ1 and IFN-β treatment resulted in 
pronounced and long-lasting antiviral effects exemplified by significantly reduced 
viral copy numbers and diminished infectious progeny. This was associated with 
strong up-regulation of multiple ISGs. However, in contrast to the IFN-β induced 
expression of ISGs, which decreased over time, expression of ISGs induced by IFN-
λ1 was sustained or even increased over time.    
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Conclusion 
Here we demonstrate that the protective potential of IFN-λ1 is comparable to IFN-
β. Yet, the long-lasting induction of ISGs by IFN-λ1 and most likely less incitement 
of side effects due to more localized expression of its receptors could make it an 
even more promising candidate for prophylactic treatment than IFN-β.   
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Introduction 
 
Acute exacerbations are the major cause of morbidity and mortality in chronic 
respiratory diseases like asthma and chronic obstructive pulmonary disease 
(COPD). Also, they increase the economic burden because of extra healthcare, 
which has to be provided to the patients [1,2]. Among others, viral infections, 
especially infections with human rhinovirus (HRV), are strongly implicated as 
important triggers for the induction of acute exacerbations [3-6]. Following HRV 
infections, healthy individuals develop upper respiratory symptoms (common cold) 
but patients with chronic respiratory diseases frequently develop more severe 
lower respiratory tract symptoms [7,8]. 
The airway epithelium provides the first line of defense against invading 
pathogens. In response to viral infections, airway epithelial cells become activated 
and start producing different antiviral mediators and pro-inflammatory cytokines. 
These mediators and cytokines not only combat invading viruses, but also recruit 
and activate other immune cells and initiate mechanisms of adaptive immunity 
[9,10]. Three different types of interferons (type-I [IFN-α/β], type-II [IFN-γ] and the 
more recently discovered type-III [IFN-λ]) are among the most important antiviral 
mediators produced by epithelial cells. Although all three types have antiviral 
properties, type-I and type-III are the IFNs which are produced in direct response to 
viral infection [11-14]. Nonetheless, type-III IFNs are considered to be more 
important for mucosal antiviral defense, while type-I IFNs might be more important 
for clearance of systemic viral infections [15,16].  
Viral infections result in the activation of transcription factors like nuclear 
factor kappaB (NFκB) and interferon regulatory factor (IRF) –3 and IRF-7, which 
regulate the production of IFNs at the transcriptional level. Yet, different subtypes 
of IFNs respond differently to IRF-3 and IRF-7. Transcription of IFN-λ1 (type-III) and 
IFN-β (type-I) genes is controlled by both IRF-3 and IRF-7, while transcription of 
other subtypes genes (type-III IFN-λ2/3 and type-I IFN-α) is predominantly 
regulated by IRF-7 [17]. This differential regulation plays an important role in the 
kinetics of induction of different subtypes. IRF-3 is constitutively and ubiquitously 
expressed in human cells. Due to this, when activated upon viral entry, it up-
regulates the expression of IFN-λ1 and IFN-β. In contrast, IRF-7 is not constitutively 
expressed in most cells and is induced in response to IFNs. Because of this IFN-λ1 
and IFN-β behave as early response genes while IFN-λ2/3 and IFN-α genes are 
expressed with delayed kinetics [18,19].  
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Deficient production of IFNs has been observed in cells isolated from 
asthma and COPD patients upon HRV infections [8,20]. This indicates an impaired 
antiviral response which makes these patients more susceptible to viral infections 
and which may ultimately lead to the induction of acute exacerbations. 
Unfortunately, currently available strategies and therapies for the prevention and 
treatment of virus-induced acute exacerbations have limited efficacy [21] and new 
options need to be explored. One potential therapeutic strategy could be the 
prophylactic exogenous administration of IFNs. 
In a previous in vitro study, we have shown that exogenous application of 
low amounts of IFN-β induces pronounced and long-lasting protective effects 
against HRV infections in human respiratory epithelial cells [22]. Alternatively, 
despite the increasing recognition of the importance of type-III IFN in airway 
antiviral defense [9,16,23,24], their potential as prophylactic agents still needs to 
be evaluated. In the present study we evaluated the potential protective effects of 
IFN-λ1 against HRV1B infection in airway epithelial cells and compared it with the 
protective effects of IFN-β. 
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Materials and Methods 
Cell Culture 
A549 cells (ATCC CCL-185; Rockville, MD, USA) were cultured in RPMI 1640 medium 
(Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal calf serum (FCS; 
Lonza, Verviers, Belgium) and incubated at 37
o
C/5% CO2.  
Primary bronchial epithelial cells (PBECs) were isolated from bronchus 
rings obtained from patients who underwent surgery for solitary pulmonary 
nodules. Lung tissues used for isolation were located at the remotest possible 
distance from the nodule and were macroscopically cancer free. PBECs were 
isolated and cultured as previously described [25]. Tissue was obtained from the 
Maastricht Pathology Tissue Collection (MPTC). Collection, storage and use of 
tissue and patient data were performed in agreement with the "Code for Proper 
Secondary Use of Human Tissue in the Netherlands" (http://www.fmwv.nl). 
Patient’s characteristics are summarized in table S1. 
MRC5 cells (ATCC CCL-171) were maintained in EMEM (Invitrogen, Grand 
Island, NY, USA) supplemented with non-essential amino acids (MP Biomedicals, 
Solon, Ohio, USA) L-glutamine (2 mM) and 10% FCS (Lonza, Verviers, Belgium). Cells 
were incubated at 37
o
C/5% CO2.  
Ethics Statement 
After reviewing the protocol within the context of the Medical Research Involving 
Human Subjects Act, the local Medical Ethics Committee of the Maastricht 
University Medical Center (METC azM/UM) waived the need for ethical approval or 
informed consent.  
Virus Culture 
HRV1B was purchased from American Type Culture Collection (ATCC, VR-1645). 
Viral stocks were generated as previously described [22]. Briefly, MRC5 were 
infected in EMEM with 2% FCS, non-essential amino acids, L-glutamine (2 mM). 
Once 100% cytopathogenic effect (CPE) was obtained, cell debris was removed by 
centrifugation and viral titers were determined by TCID50 (50% tissue culture 
infectivity dose) on MRC-5 cells. 
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Respiratory syncytial virus A2 (RSV) was obtained from the Netherlands 
Vaccine institute and propagated on Vero cells. After 2h of infection, cells were 
washed and incubated further in DMEM with 1% FCS until > 80% CPE was attained. 
Cell debris was removed by centrifugation for 10 minutes at 1000 x g. The virus 
pool was then precipitated using polyethylene glycol (PEG): PEG stock (50% 
PEG6000 in 150 mM NaCl, 1 mM EDTA, 6.1 g/L TRIS, pH 7.5), was mixed with the 
virus pool to achieve a final concentration of 10% PEG (1:5), stirred 2h at 4
o
C, 
centrifuged 30 min at 3000 x g and the pellet was resuspended in PBS + 25% 
sucrose (10% of original volume = 10 x concentrated). Viral titers were determined 
by TCID50. 
Determination of cytotoxicity of IFNs 
Because in some experiments cells were cultured for more than 100 hours in the 
continuous presence of either IFN-  or IFN-λ1, cytotoxic effects of both cytokines 
were determined with a colorimetric thiazolyl blue tetrazolium bromide (MTT) 
(Sigma-Aldrich, St. Louis, MO, USA) assay as described previously [22]. Briefly, A549 
cells were seeded in a 96-well plate and exposed for 114h to IFN-β (500 IU/ml) or 
IFN-λ1 (500 ng/ml). Afterwards the MTT assay was performed according to the 
manufacturer’s instructions. The percentage of metabolic activity of exposed A549 
cells was calculated by comparing to non-exposed controls (absorbance exposed/ 
absorbance non-exposed x 100%). 
Protective effects of IFN-β/-λ1 treatment  
Recombinant human IFN-β and IFN-λ1 were purchased from PBL Biomedical 
Laboratories (NJ, USA). In order to determine the maximum protective potential of  
the two IFNs, dose-dependent induction of ISGs was determined in A549 cells. 
Maximal expression of ISGs was achieved at 500 IU/ml for IFN-β and at  500ng/ml 
for IFN-λ1 (Fig. S1).  These doses of the respective IFNs were therefore used in all 
further experiments. The protective effect of IFNs against HRV infections was 
examined in 2 different experimental approaches (Fig. S2). In all cases, A549 cells 
were seeded in 24-well tissue culture plates (Becton Dickinson, NJ, USA) at a 
density of 2 x 10
5 
cells per well in RPMI 1640 (10% FCS). After 24h, the medium was 
replaced by fresh RPMI 1640 (2% FCS) and the experiments were started. 
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IFN pre-treatment 
In the first approach, cells were pre-treated with either IFN-λ1 or IFN-β for 18h. 
Then IFN-containing medium was replaced with fresh IFN-free medium and cells 
were infected immediately with HRV1B at a multiplicity of infection of 1 (MOI-1) for 
4h at 33
o
C/5%CO2. Also, to examine how long the protective effect of the pre-
treatment was maintained, we incubated cells for another 72h after pre-treatment 
before infection. After 4h of infection, HRV1B containing medium was removed and 
replaced by fresh IFN-free medium. Cells were cultured for another 24h and then 
collected and processed for further analyses.  
 
Continuous exposure 
Although the approach described above may reveal important information 
regarding the antiviral properties of the two types of IFN, it may not reflect the 
natural course of both treatment and infection. Therefore we also performed a 
series of experiments in which neither the cytokine nor the virus was removed 
once added. Thus, after the 18h pre-treatment period, HRV1B (MOI-1) was added 
to the cells in the continuous presence of either IFN-λ1 or IFN-β and cells were 
cultured for another 24h in the presence of IFN-β, IFNβ+HRV1B, IFNλ1 or 
IFNλ1+HRV1B. After this infection period cells were washed and collected for 
further analyses. Also, the long-lasting effect of IFN-β or IFN-λ1 treatment was 
examined when cells were infected after 72h of IFN treatment. 
For PBECs, cells were seeded in Greiner 24-well plates in BD medium 
(contains 50% DMEM (Gibco) and 50% bronchial epithelial basal medium (BEBM, 
Lonza) supplemented with BEGM SingleQuots (Lonza) and BSA (1.5μg/ml; Sigma). 
When cell layers were approximately 80% confluent, growth medium was replaced 
with BD starvation medium (BD medium without EGF, BPE, BSA and gentamicin) 
and the treatment with IFNs was initiated 24h later. Cells were then treated for 18h 
with either IFN-λ1 or IFN-β and subsequently infected with HRV1B as described 
above. In PBECs the long-lasting effect of either pre-treatment or continuous 
treatment could not be examined because of deterioration of cell viability after 72h 
of culturing. 
RSV infection and poly (I: C)/LyoVec treatment 
With the purpose of determining the induction of IFN expression in response to 
stimuli other than HRV1B, cells were infected with RSV at MOI-1 for one hour at 
37
o
C or stimulated with 500 ng/ml of poly (I:C)/Lyovec (low molecular weight) 
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(Invitrogen) and incubated at 37
o
C/5%CO2 for 24h. With poly (I:C)/Lyovec, A549 
were stimulated for 18h. Afterwards cells were collected and processed for further 
analyses.  
TCID50  
Virus titration assay was performed as previously described [26] with some 
modifications. Supernatants from infected PBECs were collected and serially 
diluted 1:2 in MEM containing 2% FCS (Lonza, Verviers, Belgium), non-essential 
amino acids and L-glutamine (2 mM). Dilutions were added on confluent MRC-5 in 
96-well plates. Each dilution was assayed in six wells and TCID50 was calculated 
according to Spearman-Karber formula.  
Plasmid construction for the generation of standard curves 
For determination of the actual number of viral RNA copies present in the cells, a 
plasmid was constructed as previously described [27] with some modifications. In 
summary, after reverse transcription of viral RNA, a PCR was performed. The PCR 
fragment was cloned into the pGEMT-easy vector (Promega) and sequenced. The 
resulting plasmid, designated p1123, was transcribed in vitro and the resulting RNA 
was quantified. Serial dilutions of the quantified RNA were used for the generation 
of a standard curve. 
 Quantification of virus load in infected cells 
Total RNA was isolated with RNeasy kit (Qiagen, Hilden, Germany) according to 
manufacturer’s instructions. After DNase treatment (Turbo DNA-free kit, Ambion, 
Austin, TX, USA), the amount of RNA in the samples was quantified with a 
Nanodrop ND-1000 and 1µg of RNA was reverse transcribed into cDNA using the 
iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA). qPCR was performed to 
amplify cDNA as described previously [28]. For HRV and the IFN genes, cDNA was 
amplified in a volume of 25μl containing IQ Supermix (Bio-Rad, Hercules, CA, USA). 
For all other genes, HOT FIREPol EvaGreen qPCR mix plus (Solis Biodyne, Tartu, 
Estonia) was used. The sequences of the primers are given in table S2. For 
determination of viral RNA copy numbers, standard curves were generated for 
every qPCR run along with the samples. Gene expression was normalized to β-actin 
level and fold changes were calculated by using 2
-ΔΔCt
 method. In case basal 
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expression of a gene was not detectable, expression was expressed using the 2
-ΔCt
 
method [29]. 
Statistical analysis  
The overall significance of the experimental effect was determined by Kruskal-
Wallis tests. Once overall significance was achieved, the differences between 
multiple groups were analyzed by Mann-Whitney test. Values of p < 0.05 were 
considered statistically significant for both Kruskal-Wallis test and Mann-Whitney 
test. Data are expressed as mean ± SEM.  
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Results 
Long term exposure to recombinant IFNs has no toxic effects on A549 cells 
Since our experimental design involved long-term exposure of cells to IFNs, 
possible toxic effects of this exposure were determined first. For this, cells were 
exposed to IFNs for about 114h, which was the maximum time for which the cells 
were to be exposed to IFNs in our main experiments. After that, metabolic activity 
of cells was determined by MTT test as an indication of cellular viability. No 
significant differences were observed between IFNs exposed and non-exposed 
cells. This indicates that long term IFNs exposure has no negative effect on the 
viability of cells (Fig. S3). 
IFN-λ1 induces strong antiviral state in A549 cells 
In our previous study we have shown that exogenous administration of IFN-β 
induced a strong up-regulation of ISGs in respiratory epithelial cells [22]. Previously, 
ISGs have been shown to contribute significantly to antiviral defense [30]. Here we 
demonstrate that in vitro treatment of A549 cells for 18h with IFN-λ1 likewise 
induces a significant up-regulation of various ISGs (Fig. 1A). Though our initial dose-
response evaluation experiments showed maximum induction of ISGs mRNA levels 
at 500 ng/ml of IFN-λ1, they were significantly lower as compared to IFN-β. 
Therefore, in the following experiments we examined whether the IFN-λ1 induced 
up-regulation of ISGs is sufficient to protect cells against a subsequent viral 
infection. 
 IFN-λ1-induced antiviral state protects against HRV1B infection 
Next we tested the antiviral potency of IFN-λ1 and compared it to the previously 
demonstrated potency of IFN-β. Therefore A549 cells were first treated with IFNs 
for 18h and then infected with HRV1B according to two different protocols. 
 
- Pre-treatment only 
First, and in line with other papers demonstrating a protective effect of IFNs [31], 
we only pre-treated cells for 18h with either IFN-λ1 or IFN-β, removed the IFN 
containing medium and then infected them for 4h with HRV1B. After another 24h, 
cells were collected and HRV1B RNA copy numbers were determined. Figure 1B 
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clearly demonstrates that both IFNs protected the cells against HRV1B infection, as 
HRV RNA copy numbers were significantly lower in IFN pre-treated cells when 
compared to untreated cells. This decrease in viral copies tended to be more 
pronounced in IFN-β treated samples when compared to IFN-λ1, which 
corresponds with a more pronounced up-regulation of ISGs in IFN-β treated 
samples as compared to IFN- λ1 (Fig. 1A). 
 
 
Figure 1. IFN-induced antiviral state protects against HRV1B infection in A549: A549 were treated with 
IFNs for 18h and then mRNA expression of different ISGs was determined by qPCR (n=6). Fold-changes 
were calculated with the 2-ΔΔCt method (A). A549 were first treated with IFNs for 18h. Next, according to 
the continuous and pre-treatment approaches, cells were infected with HRV1B and incubated for 
another 24h (n=6). After that, cells were collected for further analyses. Viral copies were determined by 
qPCR and fold-changes were calculated with the 2-ΔΔCt method (B). *, p<0.05 Control vs IFNs, HRV1B vs 
IFNs+HRV1B.  # p<0.05 IFN-λ1 vs IFN-β. 
 
- Continuous exposure 
Although pre-treatment followed by an infection for a limited time is a well-
accepted model in literature, it may not reflect the natural course of both 
treatment and infection. Therefore, in an attempt to mimic the in vivo situation 
more closely, we first treated cells with either of the IFNs for 18h and subsequently 
infected them with HRV1B in the continuous presence of the IFNs. Also, virus was 
not removed after 4h as in the pre-treatment protocol, but was kept present in the 
incubation medium until cells were collected (after 24h). As expected, at 24h after 
infection viral copy numbers were markedly higher in the untreated cells when 
compared to cells infected for only 4h (4h: 3.6 x 10
4
 vs. 24h: 2.0 x 10
5
 copies/µg 
RNA). Nevertheless, despite these higher viral copy numbers, both types of IFNs 
were still able to reduce the number of HRV RNA copies significantly (Fig. 1B). 
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IFN-λ1-induced antiviral state provides long-lasting protection against HRV1B 
infection 
Previously, we have shown that exogenous administration of IFN-β provides a long-
lasting protection against viral infection [22]. After confirming that cells were 
protected against a viral infection immediately after IFN-λ1 treatment, we aimed to 
explore whether IFN-λ1 also has the potential to provide a long-lasting protection. 
A549 cells were therefore treated with IFN-λ1 or IFN-β for 18h only. Then the IFN-
containing medium was either washed away (pre-treatment only) and cells were 
cultured for another 72h in the absence of IFNs, or cells were cultured for another 
72h in the continuous presence of either one of the IFNs (continuous exposure). 
 
 
  
To check whether cells were still in an antiviral state, we determined the 
expression of the various ISGs under different conditions. As expected, prolonged 
continuous exposure to IFNs resulted in high levels of all ISGs determined, and no 
differences were observed between IFN-λ1 and IFN-β (Fig. 2A). Also when cells 
were only pre-treated for 18h, ISG levels were still significantly enhanced even 
after additional culturing for 72h in the absence of the IFNs. Surprisingly, ISG levels 
Figure 2. Long-lasting antiviral state induced by IFNs: 
A549 were treated with IFNs for 18h. Next, according to 
the continuous and pre-treatment approaches, cells 
cultured for another 72h and collected afterwards for 
further analyses (n=4). mRNA expression of different 
genes was determined by qPCR and fold changes were 
calculated with the 2-ΔΔCt method (A & B). Moreover, to 
evaluate the antiviral status of the cells after 72h of 
culturing, cells were infected with HRV1B and incubated 
for another 24h (n=5). After that, viral copies were 
determined by qPCR and fold changes were calculated 
with the 2-ΔΔCt method (C). *, p<0.05 HRV1B vs 
IFNs+HRV1B, control vs IFNs.  #, p<0.05 IFN-λ1 vs IFN-β. 
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were significantly higher in cells pre-treated with IFN-λ1, suggesting that the 
protective effects of this type III IFN may last longer than the effect of IFN-β (Fig. 
2B).     
To test whether this antiviral state, either after continuous exposure or 
pre-treatment only, was sufficient to protect cells against HRV infection, cells were 
infected with HRV1B for either 4h (pre-treatment protocol, cells collected after 
another 24h) or for 24h (continuous protocol) 72h after the initial IFN treatment. 
Figure 2C shows that in both conditions a significant decrease in viral copies was 
found in IFN-treated cells as compared to control cells. These data imply that a 
single treatment with IFN-λ1, like IFN-β, is able to induce an antiviral state in these 
cells, which protects them for a prolonged time (in this case 72h) against future 
viral infections. 
Priming of cells with IFNs enhances their ability to produce IFNs 
IFNs can act in an autocrine and/or paracrine way to up-regulate their own 
expression, thereby reinforcing and/or maintaining their antiviral effects 
(“priming”). In order to determine whether the observed long-lasting protective 
effect was due to this phenomenon, we determined whether treatment with either 
IFN-β or -λ1 resulted in such a (cross-) priming effect. Also, we assessed whether 
the initial IFN treatment followed by an HRV1B infection affected the induction of 
IFN-β/-λ1 expression. Cells were therefore initially treated with either IFN-β or -λ1 
for 18h and cultured for another 72h according to the pre-treatment or continuous 
protocol. Afterwards cells were either infected with HRV1B or not and cultured for 
another 24h. 
 
- Expression of IFN-β after stimulation with IFNs 
Although it has been shown previously that IFN-β priming enhanced the expression 
of IFN-β [32], we were unable to see this effect when cells were only pre-treated 
(Fig. 3A). Also, no clear evidence for cross-priming was observed as IFN-λ1 pre-
treatment did not have any significant effect on the expression of IFN-β mRNA. 
Surprisingly, subsequent infection with HRV1B also did not enhance the expression 
of IFN-β, irrespective of whether cells were pre-treated with IFN-β or IFN-λ1. 
Alternatively, when cells were stimulated with IFNs for the entire period, the 
expression of IFN-β mRNA was significantly enhanced both after treatment with 
IFN-β (8.5-fold) or IFN-λ1 (3.2-fold) (p < 0.005), indicating that (cross-)priming 
occurred after prolonged exposure. Moreover, when cells were continuously 
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stimulated and subsequently infected with HRV1B, the expression of IFN-β mRNA 
was further enhanced irrespective of the type of IFN they were first treated with 
(16.1-fold with IFN-β and 12.4-fold with IFN-λ1 (p ≤ 0.05) (Fig. 3A). 
 
 
Figure 3. Priming effect of IFNs on HRV1B-induced interferon response: A549 were first treated with 
IFNs for 18h. Next, cells were incubated for another 72h according to the continuous and pre-treatment 
approaches. After that cells were infected with HRV1B for 4h in the same medium. After the infection 
period, either same medium was maintained on the cells (continuous) or replaced by fresh medium 
(pre-treated). Thereafter, cells were incubated for another 24h and then collected for further analyses. 
mRNA levels of IFN-β (A) and IFN-λ1 (B) were determined by qPCR and fold changes were calculated 
with the 2-ΔΔCt method. HRV1B induced average IFN-β expression was 1.8 (continuous) and 0.99 (pre-
treated)  folds and average IFN-λ1 expression was 1.92 (continuous) and 0.90 folds (pre-treated). *, 
p<0.05 control vs rest of conditions. #, p<0.05 IFN vs IFN+HRV1B. n=4 
 
- Expression of IFN-λ1 after stimulation with IFNs 
We also examined whether priming resulted in enhanced expression of IFN-λ1 (Fig. 
3B). In contrast to priming with IFN-β, we noticed a significant increase in the 
expression of IFN-λ1 mRNA even when cells were only pre-treated for 18h and 
collected at the end of the experiment (27.5-fold with IFN-λ1 and 11.8-fold with 
IFN-β) (p < 0.01). However, no further increase was observed when cells were 
additionally infected with HRV1B (22.0-fold with IFN-λ1 and 6.3-fold with IFN-β).  
On the other hand, continuous stimulation with either of both cytokines was 
sufficient for a significant induction of the expression of IFN-λ1 mRNA (90-fold with 
IFN-λ1 and 180-fold with IFN-β) (p < 0.005), which was further increased as a result 
of HRV1B infection (460-fold with IFN-λ1 and 513-fold with IFN-β) (p < 0.05).  
Summarizing, we noticed a strong (cross-) priming effect of IFN-β and IFN-λ1 on the 
expression of IFN-λ1. In contrast, IFN-β seemed less prone to (cross-)priming.  
 
Chapter 2                                                                                   Antiviral response of IFN-λ1 
Page | 50  
 
HRV1B does not induce an interferon response 
In the previous experiment we intriguingly noticed that the expression of IFN-β was 
hardly enhanced when cells were infected with HRV1B. Usually, basal IFNs and ISGs 
mRNA levels are very low in uninfected cells and it is generally assumed that their 
expression strongly increases after viral infection. Accordingly, previous reports 
demonstrated an increase in the expression of both type I and III IFN mRNA in 
epithelial cells following HRV infection [33,34]. Surprisingly, however, we did not 
observe such an increase in the expression of these genes in the experiments 
described above.  To further explore this observation, we infected A549 cells for 4h 
and determined the expression of IFN-β/-λ1 and various ISGs after 24h. However, 
as already shown in experiments described above, no induction of any of the ISGs 
was observed even when HRV1B was continuously present for the entire 24h 
period (Fig. 4A). Similarly, no change in IFN-β expression was found while IFN-λ1 
levels remained undetectable. Infection with another ssRNA virus, RSV, or 
stimulation with the viral mimic polyI:C/LyoVec both resulted in the induction of 
IFN genes, indicating these cells are well able to produce type I and III IFNs (Fig. 4B).  
 
 
Figure 4. HRV1B induced interferon response in A549: A549 were infected with HRV1B for 4h and 
collected after 24h, or for the whole experimental procedure (n=6). The mRNA expression of ISGs was 
determined with qPCR and fold changes were calculated with the 2-ΔΔCt method (A). Cells were infected 
with RSV (MOI-1, 1h) or HRV1B (4h). After infection, virus containing medium was removed and 
replaced with fresh medium. Then cells were collected after 24h (n=5). While with poly(I:C)/LyoVec (500 
ng/ml), cells were collected after 18h of stimulation (n=3). IFNβ/λ1 mRNA expression was determined by 
qPCR and fold changes were calculated with the 2-ΔΔCt method (B). *, p<0.05 control vs rest of the 
conditions.  
IFN-λ1 induces an antiviral state in PBECs which provides protection against 
HRV1B infection 
Although A549 cells are basically human alveolar epithelial cells, they were 
originally derived from an alveolar adenocarcinoma, and it can therefore not be 
excluded that they respond differently to external stimuli than primary cells. 
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Moreover, A549 cells are of alveolar origin while bronchial epithelial cells come in 
contact with infectious agents before alveolar cells. Therefore, to put our results 
with A549 cells into perspective, we repeated some of the experiments with PBECs. 
First we also infected these cells with HRV1B for either 4 or 24h and in line with our 
results found in A549 cells, we were unable to detect an up-regulation of IFN-β, 
IFN-λ1 or any of the ISGs. Nonetheless, similar to A549, PBECs were also able to 
express IFNs in response to stimulation with poly (I: C)/LyoVec or to a viral infection 
as RSV (Fig. 5A, B). The results both in A549 as well as the primary cells strongly 
suggest that HRV1B is to some extent able to evade the host antiviral response in 
our experimental settings.  
 
 
Figure 5. HRV1B induced interferon response in PBECs and its comparison with other stimuli: PBECs 
were infected with HRV1B for 4h and collected after 24h, or for the whole experimental procedure 
(n=4). The mRNA expression of ISGs was determined with qPCR and fold changes were calculated with 
the 2-ΔΔCt method (A).  
Cells were infected with RSV (MOI-1, 1h) or HRV1B (4h). After infection, virus-containing medium was 
removed and replaced with fresh medium. Additionally, cells were stimulated with poly(I:C)/LyoVec (500 
ng/ml) for 24h (n=3). Then cells were collected and IFNβ/λ1 mRNA expression was determined by qPCR 
and relative amount of mRNA was calculated with the 2-ΔCt method (B). *, p<0.05 control vs rest of the 
conditions.  
 
Next, we tested whether IFN treatment was able to protect primary cells 
against HRV infection. Therefore, cells were pre-treated for 18h and then infected 
with HRV1B according to the pre-treatment or continuous protocol. Figure 6A 
shows that, like in A549 cells, both IFNs were well able to protect PBECs against 
HRV1B infection as viral RNA levels were noticeably reduced in pre-treated cells 
when compared to control cells. In line with this is the pronounced up-regulation of 
ISGs as shown in figure 6B. To further confirm the protective effect of IFN pre-
treatment, we determined the generation of infectious viral particles. Again, and in 
accordance with viral RNA copy numbers, generation of infectious viral particles in 
IFN-treated cells was significantly lower as compared to non-treated samples (Fig. 
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6C). It should be mentioned that we were unable to test whether IFNs also had a 
long-lasting protective effect in PBEC because of viability issues when primary cells 
were cultured for more than 72h regardless of IFN treatment. 
 
 
       
  
 
 
 
 
 
 
 
  
 
 
Figure 6. IFNs-induced antiviral state protects 
against HRV1B infection in PBECs: PBECs were 
infected with HRV1B for 4h. After infection period, 
medium was either maintained on the cells 
(continuous) or replaced with fresh medium (pre-
treated). After that cells were incubated for another 
24h. Then the supernatant was collected to 
determine TCID50 (C) while cells were collected to 
determine viral copies (A). PBECs were treated with 
IFNs for 18h and then mRNA expression of different 
ISGs was determined by qPCR. Fold changes were 
calculated with the 2-ΔΔCt method (B). *, p<0.05 
control vs rest of the conditions n=4.  
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Discussion 
 
In this study we assessed the efficacy of IFN-λ1 to protect respiratory epithelial 
cells against HRV1B infection and compared its effects to the previously reported 
protective effects induced by IFN-β. Results of the current study revealed that 
exogenous administration of both IFNs, irrespective of how cells had been treated 
(pre-treatment vs. continuous), induced a strong antiviral state in both A549 and 
PBECs, which was associated with a robust up-regulation of various ISGs. This 
antiviral state provided efficient protection against subsequent viral infection in 
both conditions. Yet, as compared to IFN-β, the IFN-λ1- induced antiviral state 
seemed to strengthen itself over time, as the expression of ISGs induced by IFN-λ1 
was either sustained or even increased, while expression of IFN-β-induced ISGs 
decreased over time.  
Type-III IFNs are relatively recently discovered members of the IFN family. 
Like type-I IFNs, type-III IFNs have also been shown to be induced by viral infections 
and to possess antiviral properties. Although type-I and type-III IFNs act through 
different receptors, both types of IFNs activate similar intracellular signaling 
pathways and because of this, they largely have similar biological activities. Both of 
them up-regulate the expression of ISGs, which are presumably responsible to 
provide antiviral resistance to the cells [35,36]. However, not all types of cells 
respond to type-III IFNs, which is due to the fact that expression of receptors for 
type-III IFNs is limited to a few types of cells. Epithelial cells in the respiratory, 
gastrointestinal and reproductive tract are considered to be the primary cells which 
express receptors for type-III IFNs [15,37]. Particularly in the respiratory tract, type-
III IFNs have been shown to be important mediators in response to respiratory viral 
infections [16,23,24]. In this study we investigated whether type III IFNs have a 
potential as prophylactic agents against viral infections. 
We and others have previously demonstrated that IFN-β treatment of 
respiratory epithelial cells induces a strong antiviral state in these cells which 
markedly protects them against viral infections. This antiviral condition was 
noticeably associated with a distinct up-regulation in the expression of various 
ISGs. In the present study we demonstrated similar effects when cells were treated 
with IFN-λ1 resulting in a 200- to 700-fold up-regulation in the expression of all ISGs 
examined. Although this up-regulation was significantly less than the effects 
induced by IFN-β, it was still sufficient to protect the cells from a subsequent 
HRV1B infection. Interestingly, in primary cells the effects of both IFNs were quite 
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comparable, as no significant differences were found in the up-regulation of all 
ISGs, the presence of viral copies in the cells or the release of infectious progeny.  
Induction of ISGs by type-I and –III IFNs is mainly dependent on the 
activation of the Jak/STAT signal transduction pathway [36,38]. Differences in the 
activation of the Jak/STAT pathway by type-I and type-III IFNs have already been 
reported. Earlier, Maher and colleagues [39] have shown that continuous 
treatment of human keratinocyte cell line HaCat with IFN-λ1 resulted in sustained 
activation of STAT1 and STAT2 over the course of 24h. On the contrary, treatment 
with IFN-α, a type-I IFN, resulted in transient activation of STAT1 and STAT2. This 
could be due to differential regulation of type-I and type-III signaling. They also 
showed that expression of IFN-λ1 induced ISGs continued to increase at 24h. In the 
present study, we also observed differences in the kinetics of induction of ISGs by 
IFN-β and IFN-λ1. The protective effect induced by an 18h pre-treatment with both 
types of IFNs was persistent and long-lasting. Even when cells were cultured in the 
absence of the IFNs for an additional 72h after the 18h pretreatment period, cells 
were significantly protected against a subsequent HRV infection. However, when 
cells were pre-treated with IFN-β, the expression of most of the ISGs peaked 
immediately after the 18h pre-treatment period and declined significantly when 
cells were cultured for another 72h in the absence of IFN-β. In contrast, when cells 
were pre-treated with IFN-λ1, the expression of all ISGs remained constant or was 
even increased after an additional 72h of culturing in the absence of IFN-λ1. We did 
not determine the activation status of STAT1/STAT2, yet data of mRNA expression 
of IFNs presented in figure 3 show that the observed expression of ISGs is in line 
with the expression of IFNs. Also, it shows that IFN-λ1, in contrast to IFN-β, is well 
able to induce its own expression. This supports the findings of Ank and colleagues 
who demonstrated that both type I and type III IFNs are able to (cross-)induce the 
expression of type III IFNs but not type I IFNs [12]. However, in contrast to Ank et. 
al., we also observed an up-regulation of the IFN-β expression in response to long 
term stimulation with both IFN-β itself and also with IFN-λ1, both in the presence 
or absence of infectious agent HRV1B (continuous scenario). In the presence of 
HRV1B the  increase in the IFN-β expression could be mediated by IRF-7, as both 
IFN-β and -λ1 can prime IRF-7, which will subsequently result in virus-induced 
nuclear translocation and  increased transcription of IFNs [18,32,40]. Nonetheless, 
in the absence of a virus, the increase in the IFN-β expression could be driven by 
IRF-1. IRF-1 can be up-regulated by IFNs and then can induce IFN-β [41,42]. Due to 
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this characteristic of IFN-λ1, the strength of the antiviral state induced by this type 
of IFN may be maintained for a prolonged period. 
In order to replicate in host cells, viruses have evolved different strategies 
to subvert the host interferon response. Also HRVs have been shown to have this 
ability. For example, when A549 cells were infected with HRV14 only low levels of 
IFN-β mRNA were induced as compared to those induced by vesicular stomatitis 
virus [43]. This attenuation of the antiviral response by the virus was shown to be 
due to interference with IRF3 activation. Similar results were found when HeLa cells 
were infected with HRV1a [44]. Consistent with these observations, one very 
recent study also showed no induction of IFN-β after HRV1B infection in primary 
bronchial epithelial cells, which were isolated from healthy persons [45]. Likewise, 
in the present study, we also did not observe an up-regulation of the IFNs or ISGs 
mRNA expression after infection of A549 or PBECs with HRV1B. In contrast, when 
PBECS were infected with RSV or were stimulated with poly(I:C)/LyoVec, a synthetic 
ligand for intracellular sensors of viral RNA, RIG-I and MDA5, we found a strong up-
regulation in the expression of both IFN-β and IFN-λ1 mRNA. Similar results were 
observed in A549 cells. This indicates that cells are well able to respond to viral 
stimuli and are capable to mount both a type-I and a type-III IFN response. 
Furthermore, up-regulation of ISGs in response to IFN treatment shows that IFN 
signaling in these cells was also intact. These data suggest that HRV is able to 
actively interfere with the IFN-dependent antiviral response in respiratory 
epithelial cells. Nevertheless, this finding is in conflict with data published by 
several other groups who demonstrated a moderate to strong up-regulation of IFN-
β mRNA expression [34,46]. The reason for this discrepancy is not clear, but could 
be due to different experimental conditions, different virus strains/stocks or 
different types or sources of cells. In this study we did not further explore this 
inconsistency between different studies as it was beyond the scope of the present 
study, but further investigations are required to unravel the reason for these 
differences. 
Altogether, these data indicate that both IFN-β and IFN-λ1 are able to 
provide protection against viral infection with comparable efficacy. However, 
because of the more restricted distribution of its receptors to the epithelial lining in 
particular of the respiratory tract, and a sustained long-term induction of ISGs, IFN-
λ1 therapy can have a more important role in the prevention of viral infections with 
probable causation of fewer side effects. Yet, further work is required in particular 
regarding the efficacy of the cytokine in an in vivo setting.    
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Supplementary figure-1: Dose titration of IFNs 
 
A549 were treated with IFN-β (25, 100, 500 and 1000 IU/ml) (A) and IFN-λ1 (25, 100 and 500 ng/ml) (B) 
for 18h. mRNA expression of different ISGs was determined by qPCR (n=4). Fold-changes were 
calculated with the 2-ΔΔCt method. 
Supplementary figure-2: Schematic representation of treatment with IFNs and 
HRV1B infection protocol. 
 
Cells were first treated with IFNs for 18h. After that, two different approaches were followed for 
infection with HRV1B: i) Pre-treated: IFNs containing medium was replaced with fresh IFN-free medium. 
Next, for immediate subsequent infection, cells were infected with HRV1B for 4h (A), while for 
determining the long lasting protective effect, cells were incubated for another 72h and then infected 
with HRV1B for 4h (C). After infection period, virus-containing medium was replaced with fresh IFN-free 
medium and cells were incubated for another 24h. ii) Continuous: After 18h treatment with IFNs, for 
immediate subsequent infection cells were infected with HRV1B in the same medium for another 24h 
(B) while to determine long lasting protective effect cells were infected after 72h in the same medium 
(D) and incubated for another 24h. 
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Supplementary Figure-3: Toxicity of IFNs in A549 cells. 
 
A549 cells were exposed to IFN-λ1 (500 ng/ml) or IFN-β (500 IU/ml) for 114h. Metabolic activity of IFN-
treated and non-treated cells was determined by MTT assay and compared to each other. Data are 
represented as mean +/- SEM of three independent experiments. 
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Supplementary table 1. Patient characteristics 
Number of patients 4 
Age in Years 69.5 (65 – 75) 
BMI (kg/m
2
) 27.8 (20 – 35.26) 
Sex (F = female, M = male) F:1 : M:3 
Current smokers 0 
Second-hand smoker exposure 1 
Ex-smoker 1 
Pack-years smoked  15 (0 – 40) 
FEV1 in % predicted 114.6 (87.8 – 137.2) 
FVCin in % predicted 114.1 (77.7 – 141.3) 
Tiffeneau-Index 82.9 (74.8 – 105) 
BMI = Body Mass Index; FEV1 = Forced expiratory volume in 1 second; FVCin = 
inspiratory forced vital capacity 
 
Supplementary table 2. Primers used for mRNA expression analysis 
Gene      Primer sequences (5’-3’) 
RV forward 
reverse 
TGGACAGGGTGTGAAGAGC 
CAAAGTAGTCGGTCCCATCC 
ISG15          
            
forward   
reverse 
GGTGGTGGACAAGTGCGATG 
CGAAGGTCAGCCAGAACAGG 
Mx1      
   
forward  
reverse 
GGACATCGCCACCACAGAGG 
TCCGCACCACATCCACAACC 
OASL                                  
 
forward                                                               
reverse                      
TGGGATCTTCTCCCACACTC 
ATAGATCCCCAGACCCAACC 
Viperin                                                 
 
forward                                                          
reverse   
AAGCGCATATATTTCATCCAGAATAAG 
CACAAAGAAGTGTCCTGCTTGGT 
IFN-β                          
 
forward   
reverse  
AAATTGCTCTCCTGTTGTGC 
TGCAGCTGCTTAATCTCCTC 
IFN-λ1                           
  
forward                     
reverse             
GGACGCCTTGGAAGAGTCACT 
AGAAGCCTCAGGTCCCAATTC 
β-actin                      
  
forward                                                 
reverse              
TGGAGAAATCTGGCACCAC   
GAGGCGTACAGGGATAGCAC 
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Abstract 
Background 
Administration of exogenous interferons (IFNs) to prevent virus-induced 
exacerbations in patients of asthma and chronic obstructive pulmonary diseases, 
could be a therapeutic option. However, the effect of IFNs on the inflammatory 
response of airway cells, which is a core feature of exacerbations, is not completely 
understood. In the present in vitro study, we evaluated the effect of exogenous 
IFN-lambda1 (IFN-λ1) and IFN-beta (IFN-β) on the inflammatory response of 
macrophages and epithelial cells in mono- and co-cultures, in terms of production 
of interleukin 6 (IL-6) and interleukin 8 (IL-8).  
Methods 
Type-II like epithelial cells (A549 cell line) and THP-1-derived macrophages were 
pre-treated with type-III IFN (IFN-λ1, 500 ng/ml) and type-I IFN (IFN-β, 500 IU/ml) 
for 18h in mono- and co-cultures. To determine the effect of pre-treatment with 
IFNs on the inflammatory and antiviral response upon viral infection in co-cultures, 
cells were infected with respiratory syncytial virus (RSV) after pre-treatment with 
IFNs. Media and cells were collected and analyzed further with qPCR and ELISA.   
Results 
In mono-cultures, IFNs did not affect IL-6 and IL-8 production in A549, whereas in 
macrophages IL-8 production was increased. In co-cultures both IFNs significantly 
increased the IL-6 and IL-8 release which was partially mediated by IL-1. Upon 
subsequent RSV infection, both IFNs significantly restricted the viral replication and 
virus-induced IL-6 and IL-8 release, with a more pronounced effect after IFN-β 
treatment. Furthermore, the release of IL-6 and IL-8, induced by each of the IFNs 
individually, was moderate when compared to amounts released in response to 
RSV alone.  
Conclusion      
Although administration of both type-I/III IFNs initiated a moderate inflammatory 
reaction in the co-culture system, the protective effects mediated by the inhibition 
Chapter 3                                                                                           Inflammatory response 
Page | 65  
 
of the viral replication and the reduction in the release of pro-inflammatory 
cytokines may be far more important. Yet, further studies are warranted to 
determine the appropriateness of exogenous IFNs to prevent virus-induced 
exacerbations in patients with chronic respiratory diseases. 
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Introduction 
 
Acute exacerbations (AEs), characterized by acute worsening of the symptoms, are 
important clinical events in chronic respiratory diseases like asthma and chronic 
obstructive pulmonary disease (COPD). These exacerbations impose a significant 
burden on the health care system and deteriorate the quality of life of the patients 
[1,2]. Respiratory infections are the major inducers of AEs and about half of these 
AEs in asthma and COPD are associated with viral infections [3,4]. These viral 
infections are accompanied by an increased airway inflammation which is an 
important feature of AEs [1,5]. Thus therapies aiming to prevent viral infections 
and reduce the inflammation could help to reduce the frequency and morbidity of 
AEs.    
Viral infections result in the induction of interferons (IFNs) by cells as 
important elements of the host innate antiviral response to control the viral 
replication [6,7]. On the basis of their amino acid sequence IFNs are divided into 
three classes, namely type-I, type-II and more recently discovered type-III IFNs. In 
human, the type-I IFNs contain only one IFN-β subtype and multiple IFN-α 
subtypes. Type-II IFN, on the other hand, has only one subtype, IFN-γ, while type-III 
IFN comprise three subtypes (IFN-λ1, -λ2 and -λ3). Among all three types, type-I 
and -III IFNs are produced in an immediate response to viral infections and are 
central to antiviral defense [8]. Although both types bind to distinct receptors 
[9,10], they activate similar intracellular signaling pathways leading to the induction 
of a similar set of genes [11,12]. However, unlike the receptors for type-I IFNs, 
which are ubiquitously expressed [13], expression of receptors for type-III IFNs is 
restricted to few cell types and mainly epithelial cells and subsets of immune cells 
are responsive to type-III IFNs [14,15]. 
Previously it has been shown that the antiviral response is impaired in 
patients with chronic respiratory diseases, as upon viral infection deficient IFN 
production has been observed in cells isolated from patients [16,17]. Inspired by 
this observation it has been suggested that strengthening the antiviral response in 
these patients might be beneficial to prevent infections and consequently AEs. 
Along this line, we have shown in previous in vitro studies that exogenous 
application of both IFN-β and IFN-λ1 provides long lasting protection against 
human rhinovirus infection in airway epithelial cells [18] suggesting that 
prophylactic treatment of patients might be an option to prevent viral infections of 
respiratory tract. Yet, the effect of exogenous IFNs on non-infected cells like 
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epithelial cells or macrophages is not completely understood and may eventually 
elicit an undesirable inflammatory reaction. For example, IFN-λ1 has been shown to 
enhance the production of inflammatory cytokines in peripheral blood 
mononuclear cells (PBMCs) [14], while IFN-β has been shown to have anti-
inflammatory properties in PBMCs [19] and bronchial epithelial cells [20].  
However, results of these studies in individual cell types may not 
completely depict the effects of the prophylactic application of exogenous IFNs to 
the respiratory tract. The respiratory tract consists of a complex network of 
different cells in which particularly macrophages and epithelial cells interact with 
each other through the production of different mediators to regulate the immune 
response [21-23]. Thus, studying the effect of prophylactic IFN treatment in co-
cultures of macrophage and epithelial cells will provide more insight on the 
inflammatory response of these cells. In the present study we treated THP1-
derived macrophages and alveolar epithelial cells (A549) with IFN-λ1 and IFN-β, 
both individually and in co-cultures, and evaluated the inflammatory response in 
terms of the release of interleukin 6 (IL-6) and interleukin 8 (IL-8). Moreover, in an 
attempt to extend our previous results in isolated cell cultures regarding the 
antiviral properties of both IFN types, we also evaluated the effect of prophylactic 
treatment with IFNs on the antiviral response of cells in these co-cultures. 
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Materials and Methods 
Culture Conditions 
The A549 alveolar type-II like cell line (ATCC CCL-185) was maintained in RPMI-1640 
medium (Gibco, life technologies, NY, USA) supplemented with 10% fetal calf 
serum (FCS; Lonza, Verviers, Belgium) at 37
o
C/5% CO2. The THP1 human monocytic 
cell line (ATCC TIB-202) was maintained in RPMI-1640 medium supplemented with 
100 mM of Sodium pyruvate, 22.5% Glucose, 25 mM 2-Mercaptoethanol and 10% 
FCS at 37
o
C/5% CO2. To differentiate THP1 monocytes into macrophages, they were 
cultured for 48h in the maintenance medium supplemented with 200 nM phorbol 
12-myristate 13-acetate (PMA). 
Mono- and co-cultures of A549 and THP1-derived macrophages  
Mono-cultures of A549 and THP1-derived macrophages were prepared by seeding 
2.5 x 10
5
 and 2.5 x 10
4
 cells, respectively, in 24-well tissue culture plates (Becton 
Dickinson, NJ, USA) in one ml of RPMI-1640 medium supplemented with 10% FCS.  
In co-culture experiments, cell suspensions containing 2.5 x 10
5
 of A549 
and 2.5 x 10
4
 of THP1-derived macrophages were prepared in one ml of the same 
medium as for mono-cultures and seeded in 24-well tissue culture plates. Both 
mono- and co-cultures were incubated at 37
o
C/5% CO2 for 24h before stimulation.  
Virus culture 
Respiratory syncytial virus A2 (RSV) was obtained from Dutch Vaccine institute and 
propagated on Vero cells. For the generation of viral stocks, cells were infected 
with RSV at multiplicity of infection of 0.5 (MOI-0.5). After 2h of infection cells were 
washed and incubated further in DMEM with 1% FCS until > 80% CPE was attained. 
Cell debris was removed by centrifugation for 10 minutes at 1000 x g. Virus pool 
was then polyethylene glycol (PEG) precipitated: PEG stock (50% PEG6000 in 150 
mM NaCl, 1  mM EDTA, 6.1 g/L TRIS, pH 7.5), mixed with virus pool to get 10% PEG 
(1:5), stirred 2h at 4C, centrifuged 30 min at 3000 x g and the pellet was re-
suspended in PBS + 25% sucrose (10% of original volume = 10x concentrated). Viral 
titers were determined by TCID50. 
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Stimulation and infection protocol 
Twenty-four hours after seeding the cells, medium was replaced with fresh RPMI-
1640 medium supplemented with 2% FCS and both mono- and co-cultures were 
stimulated with 500 ng/ml of IFN-λ1 and 500 IU/ml of IFN-β (PBL Biomedical 
Laboratories, NJ, USA) for 18h. In previous experiments, these concentrations have 
been shown to effectively prevent viral infections. Next, medium containing IFNs 
was replaced with fresh medium and cells were infected with RSV at MOI-1 for 1h 
at 37
o
C/5% CO2. Following that, virus-containing medium was replaced with fresh 
medium, and cells were incubated for another 24h at 37
o
C/5% CO2. Supernatants 
and cells were collected after 18h of IFNs stimulation and also after RSV infection at 
the end of experiment. In order to determine the role of IL-1 in the production of 
IL-6 and IL-8 by IFNs, in co-cultures cells were first pre-treated with Human IL-1-R 
antagonist (IL-1RA) (PeproTech, London) at 100 ng/ml for 2h and then stimulated 
with IFNs for 18h.  
Plasmid construction for the generation of standard curves 
In order to determine the number of viral RNA copies present in the cells, a plasmid 
was constructed as previously described [24] with some modifications. In summary, 
isolated viral RNA was reverse transcribed in the presence of both RSV primers 
(supplementary table) (SuperscriptII Reverse Transcriptase ,Invitrogen). The 
obtained cDNA fragment was amplified by PCR and then column-purified (MSB Spin 
PCRapace kit, Invitek, Germany). After that, it was cloned into the pGEMTeasy 
vector (Promega, Wisconsin, USA) and sequenced. The resulting plasmid DNA, 
designated p1092, was in vitro transcribed (T7 RNA polymerase, Fermentas) into 
RNA and then treated with DNase (DNase I recombinant, RNase free; Roche). RNA 
concentrations were determined with Nanodrop ND-1000 and copies per μl were 
calculated with Avogadro’s number. Serial dilutions of the quantified RNA were 
used for the generation of a standard curve. 
Quantitative real-time PCR 
Total RNA was extracted with FATRK 001 (Favorgen Biotech Corporation, Taiwan) 
RNA isolation kit according to manufacturer’s instructions and DNase treated with 
Turbo DNA-free kit (Ambion, life technologies, NY, USA). After quantification of 
RNA with a Nanodrop ND-1000, 1 µg of RNA was reverse transcribed with iScript 
cDNA synthesis kit (Bio-Rad, Hercules, California, USA) in a reaction volume of 20 
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µl. Quantitative real-time PCR (qPCR) was performed as previously described [25]. 
To quantify the viral RNA copies, standard curves were generated for every qPCR 
run along with the samples. β-actin levels were used to normalize the gene 
expression and fold changes were calculated with 2
-ΔΔCt
 method. In case basal 
expression of a gene was not detectable, expression was expressed using the 2
-ΔCt
 
method [26]. 
Measurement of cytokines and chemokine at protein levels 
To determine the protein levels of different cytokines within the supernatants, an 
enzyme-linked immunosorbent assay was performed according to the 
manufacturer’s instructions. For quantification of protein levels of IL-6, IL-10 and IL-
1beta (IL-1β), Human ELISA Ready-SET-Go! kits (affymetrix eBioscience, USA) were 
used. For quantification of IL-8, Human CXCL8/IL-8 Quantikine ELISA Kit (R & D 
systems, Minneapolis, USA) was used.  
Statistical analysis 
The overall significance of the experimental effect was determined by Kruskal-
Wallis tests and the differences between multiple groups were analyzed by Mann-
Whitney test, unless stated otherwise. Values of p < 0.05 were considered 
statistically significant. Data are expressed as mean ± SEM.  
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Results 
Effect of IFNs on the inflammatory response of cells 
Earlier macrophages have been shown to be responsive to IFN-λ1 [14]. Yet, before 
stimulating the cells with IFNs, we confirmed that THP1-derived macrophages 
express the interferon lambda receptor-1 at mRNA level with qPCR (data not 
shown). Next, to examine the effect of treatment of IFNs on the inflammatory 
response of THP1-derived macrophages and A549 cells, both in mono- and co-
cultures, cells were treated with either IFN-λ1 or IFN-β for 18h and protein levels of 
IL-6 and IL-8 were determined in the supernatants. 
 
Mono-cultures 
In mono-cultures of THP1-derived macrophages and A549, treatment with IFN-λ1 
or IFN-β did not have any effect on the release of IL-6 and protein levels of IL-6 
remained below detection limit of our ELISA (6.25 pg/ml). Similarly, and although 
IL-8 was detected in untreated cells, IFNs did not affect the IL-8 production in 
mono-cultures of A549 cells (Figure 1A). Mono-cultures of THP1-derived 
macrophages also released IL-8 under basal conditions and, in contrast to A549, 
treatment with both IFNs significantly enhanced the production of IL-8 (Figure 1B). 
 
 
Figure 1. Effect of treatment with IFNs on IL-8 production in mono-cultures: A549 (A) and THP1-derived 
macrophages (B) were stimulated with IFN-λ1 and IFN-β for 18h. After that supernatants were collected 
and protein levels of IL-8 were determined with ELISA. One way ANOVA with LSD and Dunnett T3 post 
hoc tests were applied to determine the difference between the groups. *, p<0.05 control vs rest of the 
conditions. n=4 for A549 and n=6 for macrophages. 
 
Co-culture 
Similar to mono-cultures, basal levels of IL-6 were also below the detection limit in 
the co-cultures. For IL-8, noticeably, already at the basal level significantly higher 
amounts were detected in co-cultures than the combined basal levels of mono-
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cultures of A549 and THP1-derived macrophages (Figure 2A), suggesting some kind 
of synergistic effect between both cell types. Next, co-cultures were stimulated 
with either of the IFNs. In contrast to the results found in mono-cultures, 
stimulation with either of the IFNs significantly induced the release of IL-6 in co-
cultures (Figure 2B). Interestingly, levels of IL-6 detected in the supernatants of IFN-
λ1-stimulated cells were significantly lower than those of IFN-β-stimulated cells. 
 
 
Figure 2. Effect of treatment with IFNs on IL-6 and IL-8 production in co-cultures: Co-cultures of A549 
and THP1-derived macrophages were stimulated with IFN-λ1 and IFN-β for 18h. After that supernatants 
were collected and protein levels of IL-6 and IL-8 were determined with ELISA. Figure A shows the 
difference between basal levels of IL-8 in co-cultures and combined basal levels of IL-8 (represented by 
dotted line) in two mono cultures of A549 and THP1-derived macrophages. Figure B and C shows the 
levels of IL-6 and IL-8 respectively, induced after IFNs stimulation in co-culture. While difference 
between levels of IL-8 induced by IFNs in co-culture and combined levels of IL-8 (represented by dotted 
line) induced by IFNs in monocultures are shown in figure D and E. *, p<0.05 control or combined levels 
vs rest of the condition/s. #, p<0.05 between indicated conditions. n=5 for figure B and C and n=4 for 
figure A, D and E. 
  
Also, levels of IL-8 in the supernatants of the co-cultures were markedly 
enhanced following stimulation with both IFNs (Figure 2C). Furthermore, similar to 
the synergism observed at the basal level in the co-cultures, also a synergistic effect 
was observed when co-cultured cells were stimulated with IFNs (Figure 2D & E). 
Remarkably, the effect of stimulation with the different IFNs regarding the IL-8 
production was opposite to IL-6 production as IFN-β treatment induced 
significantly less IL-8 than IFN-λ1 treatment (Figure 2C). This indicates that cells 
responded differently to IFN-λ1 or IFN-β regarding the release of IL-6 and IL-8. 
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Induction of IL-6 and IL-8 by IFNs is partially mediated by IL-1 
In macrophages, activation of STAT1 by IFNs plays a pivotal role in 
lipopolysaccharide induced production of IL-1β [27], which is an important 
inflammatory mediator that potentially augments the inflammatory response of 
macrophages and epithelial cells [28,29]. In order to determine whether the 
observed increased production of IL-6 and IL-8 in co-cultures after IFN treatment is 
mediated by IL-1β, expression of IL-1β was determined both at mRNA and protein 
level. Our qPCR data showed strong increase in IL-1β mRNA expression in cells, 
which were treated with IFNs as compared to non-treated cells (IFN-λ1: 76-fold 
increase, IFN-β: 16-fold increase). However, protein levels of IL-1β remained 
undetectable, regardless of whether cells were treated with IFNs or not. Yet, 
results of a previous study conducted in our lab showed that even trace amounts of 
IL-1β (~1pg/ml, below the detection limit of the ELISA), could strongly induce the 
expression of IL-8 (unpublished data). To further elucidate a potential role of trace 
amounts of IL-1 in the observed effect, cells in co-culture were pre-treated with an 
antagonist for IL-1 receptors, IL-1RA and then treated with IFNs. To our surprise, 
blocking of IL-1 receptors significantly decreased the production of both IL-6 and IL-
8 in response to treatment with IFNs (Figure 3A & B). This suggests that production 
of IL-6 and IL-8 in response to treatment with IFNs is partially mediated by IL-1. 
 
 
Figure 3. Effect of treatment with IFNs on IL-6 and IL-8 production is partially mediated by IL-1β: Co-
cultures were either pre-treated or not with IL-1RA at 100ng/ml for 2h and then stimulated with IFNs for 
another 18h. After that supernatants were collected and protein levels of IL-6 (A) and IL-8 (B) were 
determined with ELISA. Differences between the groups were determined with paired sample t test. *, 
p<0.05 between indicated conditions. n=5 
 
Effect of IFNs pre-treatment on antiviral and inflammatory response of cells to 
viral infection 
Previously, in mono-cultures of airway epithelial cells we have shown that IFN pre-
treatment protects the cells against subsequent viral infections. Here we 
investigated whether this protective effect was maintained in a more complex co-
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culture condition. Therefore, co-cultures were first pre-treated with either IFN-λ1 
or IFN-β for 18h. Then IFN-containing medium was removed and cells were 
infected with RSV at MOI-1. After another 24h supernatants and cells were 
collected. Supernatants were used to determine the levels of IL-6 and IL-8 with 
ELISA, while viral RNA copy numbers and mRNA expression of IL-6 and IL-8 were 
determined with qPCR. 
 
Antiviral effect   
In both IFN-λ1 and IFN-β pre-treated cells, significantly lower numbers of viral RNA 
copies were found as compared to control cells (Figure 4). Although it has been 
suggested previously that type-III IFNs may have weaker antiviral activity than type-
I IFNs [30], no significant differences in viral RNA copies were found between IFN-β- 
or IFN-λ1 treated cells, suggesting that both IFNs had equal potency to prevent RSV 
infections in macrophage/epithelial cell co-cultures. 
 
 
Figure 4. Antiviral response of IFN-λ1 and IFN-β in co-cultures: Co-cultures were pre-treated with IFNs 
for 18h. Then IFNs containing medium was replaced with fresh IFN-free medium. Next cells were 
infected with RSV at MOI-1 for 1h and incubated for another 24h. After that cells were collected and 
RNA copies of virus were determined with qPCR. *, p<0.05 RSV vs IFN-λ1+RSV or IFN-β+RSV. n=4 
 
Effect on inflammatory response induced by viral infection 
Detrimental effects of viral infections may either be caused by the cellular 
damage/death following viral entrance and replication or by the subsequent 
massive inflammatory reaction resulting in massive tissue damage. In order to 
determine whether the inflammatory response following infection is affected by 
pre-treatment with IFNs, both mRNA and protein levels of IL-6 and IL-8 were 
determined in the co-cultures after 24h of RSV infection. As expected in the 
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absence of viral infections, very low levels of both IL-6 and IL-8 mRNA were found. 
Pre-treatment with IFNs slightly, though significantly, increased the mRNA 
expression of both IL-6 (IFN-β: 6.57 ± 0.71 fold, IFN-λ1: 8 ± 1.19 fold) and IL-8 (IFN-
β: 1.85 ± 0.29 fold, IFN-λ1: 3.3 ± 0.79 fold). Nevertheless, despite the higher IL-6 
mRNA levels, no IL-6 was found in the supernatants. Alternatively, IL-8 was still 
detectable 24h after the pre-treatment period and remained significantly higher 
than levels found in control cells (control: 306 ± 17.06 pg/ml, IFN-β: 1208.5 ± 288.5 
pg/ml, IFN-λ1: 565 ± 42 pg/ml, p<0.05 vs. control).  
 
 
Figure 5. Effect of pre-treatment of co-cultures with IFNs on IL-6 and IL-8 induction by RSV: Co-cultures 
were pre-treated with IFNs for 18h and then IFNs containing medium was replaced with fresh medium. 
Next cells were either infected with RSV at MOI-1 for 1h and incubated for another 24h. After another 
24h cells and media were collected and expressions of IL-6 and IL-8 were determined at mRNA level with 
qPCR (A & B) and at protein level with ELISA (C & D). *, p<0.05 control vs rest of the conditions. #, 
p<0.05 between indicated conditions. n=4 
  
In RSV infected cells a strong induction of both mRNA and protein levels of 
IL-6 and IL-8 was observed irrespective whether cells were pre-treated with IFNs or 
not (Figure 5A-D). However this induction was significantly less in samples which 
were pre-treated with either IFN-λ1 or IFN-β. Noteworthy, the diminished 
expression of virus-induced IL-6 and IL-8 was more pronounced in IFN-β pre-
treated samples than IFN-λ1 pre-treated samples.  
Summarizing these results shows that pre-treatment of cells with either of 
the IFNs was not only effective to prevent viral replication but also to restrain the 
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virus-induced inflammatory response. Interestingly, the latter was more prominent 
in IFN-β pre-treated co-cultures. 
 
Is the anti-inflammatory effect of IFNs mediated by IL-10? 
IFNs can induce the expression of interleukin 10 (IL-10), which is a potent anti-
inflammatory cytokine [14,31-34]. In order to determine, whether the observed 
anti-inflammatory effect of IFNs in our co-culture model is mediated by IL-10, 
mRNA expression of IL-10 was determined after 18h of treatment with IFNs. 
Indeed, treatment with both IFN-λ1 and IFN-β significantly increased the mRNA 
expression of IL-10 (Figure 6). 
 
 
Figure 6. Effect of treatment of co-cultures with IFNs on the induction of IL-10: Co-cultures were 
treated with IFNs for 18h cells and media were collected and expressions of IL-10 was determined with 
qPCR. *, p<0.05 control vs rest of the conditions. n=4 
 
Next to see if this increase in mRNA level was also translated into IL-10 
protein, ELISA was performed after 18h of IFNs treatment and also after 24h of RSV 
infection. However, under all different conditions and at both time points, IL-10 
protein levels remained below detection levels (data not shown). To further 
investigate the role of IL-10, we pre-treated the cells with recombinant IL-10 at a 
dose of 150 times more than the detection limit of ELISA (15.6 pg/ml) for 1h and 
then infected with RSV at MOI-1. After 24h of RSV infection, protein expressions of 
IL-6 and IL-8 were determined by ELISA. Nevertheless, no difference in the 
expression of IL-6 and IL-8 were found between control co-cultures and co-cultures 
pre-treated with IL-10 (data not shown). Thus, despite the previously reported anti-
inflammatory effects of IL-10 and the significant increase in the expression of IL-10 
mRNA in IFN-pretreated co-cultures, a possible role for IL-10 in the reduced 
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expression of inflammatory cytokines in IFN-pretreated co-cultures following RSV 
infections, seems unlikely. 
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Discussion 
 
Viral infections are among the major triggers of acute exacerbations in asthma and 
COPD patients [1,5] and inflammation is the core feature of these exacerbations 
[35,36]. One therapeutic option to prevent these virus-induced exacerbations 
might be the prophylactic administration of IFNs. In a previous in vitro study, we 
have shown that treatment of airway epithelial cells either with IFN-λ1 or IFN-β 
provides a long-lasting protection against viral infection with comparable efficacy 
for both IFNs. To elaborate this in more detail, in the present in vitro study we 
evaluated the effects of IFNs treatment on the inflammatory response of A549 and 
THP1-derived macrophages in mono- and co-cultures. Also, effect of pre-treatment 
with IFNs on the inflammatory response induced by RSV infections was evaluated. 
The main finding of this study is that pre-treatment with either of the IFNs does not 
only prevent viral infections in the co-culture model, but also diminishes the pro-
inflammatory reaction following viral infections in an epithelial cells/macrophage 
co-culture. As it is anticipated that most of the damage inflicted during virus-
induced exacerbations is because of an excessive inflammatory reaction, inhibition 
of this inflammation by prophylactic IFN-β or -λ1 therapy may be of clinical 
importance.  
Previously, we and others have shown that airway epithelial cells (both 
A549 and primary cells) are responsive to the treatment of exogenous IFN-λ1 and 
IFN-β and attain an antiviral state by the strong induction of interferon stimulated 
genes (ISGs) [18,20,37]. Yet, since the respiratory system consist of more than one 
cell type, we decided to study similar processes in a more complex system in which 
we co-cultured epithelial cells and macrophages, two cell types intimately involved 
in resolving bacterial and viral infections of the respiratory tract. The importance of 
studying these specific processes in more complex systems was already illustrated 
by the finding that co-culturing both cell types resulted in a synergistic effect 
regarding the release of IL-6 and IL-8. For example, no detectable release of IL-6 
was found under basal conditions or following stimulations with IFNs in mono-
cultures of either cell type. However, when cells were co-cultured, significant 
amounts of IL-6 could be detected in the supernatants of co-cultures stimulated 
with either of the IFNs. Likewise, similar synergistic effects were observed with 
reference to IL-8. This indicates that the differentiation and/or activation state of 
cells was changed in co-culture due to the complex cross talk between the cells 
[23,38] and that they had become more responsive to the exogenous IFNs. 
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Interestingly, in response to IFN-λ1 less IL-6 but more IL-8 was released in the co-
culture system. This suggests that the release of IL-6 and IL-8 by IFN-λ1 and IFN-β is 
controlled by different mechanisms perhaps due to the use of different receptors, 
the induction of distinct signal transduction or gene regulation kinetics by IFN-λ1 
and IFN-β [39,40]. 
Interleukin-6 and -8 are among the most important inflammatory 
mediators especially in the lung. IL-6 is a cytokine which plays a key role in acute 
phase responses [41], while IL-8 is a chemoattractant which plays an important 
part in the recruitment and activation of neutrophils and other cells including 
monocytes and lymphocytes [42,43]. Exacerbations in COPD have been associated 
with increased levels of IL-6 and IL-8 [44,45]. Similarly, increased levels of IL-6 and 
IL-8 have been detected in asthmatics than non-asthmatics [42,46-48]. Therefore, it 
has been suggested that in particular excessive production of these inflammatory 
mediators by airway cells may contribute to the induction of exacerbations in COPD 
and asthmatic patients. Thus, inhibition of the release of these cytokines may be 
beneficial in preventing exacerbations. Interestingly it has been shown earlier that 
type-I IFNs are able to inhibit IL-8 induction in different cells [19,49-51]. However, 
in our setting both type I and III IFNs induced the release of both IL-6 and IL-8, 
suggesting that prophylactic administration might more detrimental than beneficial 
in preventing exacerbations. Nevertheless, levels of both IL-6 and IL-8 detected 
after treatment with IFNs were moderate (IL-6: ~100-200 pg/ml, IL-8: ~7-8 ng/ml) 
as compared to high amounts of IL-6 and IL-8 detected in the supernatants of cells 
which were infected with RSV alone (IL-6: ~3000 pg/ml, IL-8: ~25 ng/ml). This 
moderate increase in IL-6 and IL-8 production by IFNs on their own might be 
required for efficient activation of immune response and clearance of virus without 
exaggerated inflammation and destruction. More important was the observation 
that pre-treatment with both IFNs dramatically reduced the release of IL-6 and IL-8 
when cells were infected with RSV. In particular IFN-β was well able to control the 
release of both IL-6 (84% reduction) and IL-8 (87% reduction). Since both IFNs were 
equally able to reduce viral loads, it seems unlikely that this difference is solely due 
to less pronounced activation of the IL-6/8 release because of lower viral loads in 
IFN-β pre-treated co-cultures. To further unravel this we examined the possible 
involvement of IL-10 in the IFNs-induced inhibition of the IL-6 and IL-8 release. It 
has been shown that both IFN-λ1 and IFN-β are able to induce the production of IL-
10 by cells including PBMCs and bone marrow derived cells [14,31-34]. Moreover, 
IL-10 inhibits the expression of genes induced by type-I IFNs [33,52]. Similarly, IL-10 
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has been shown to inhibit IFN-λ1 induced IL-6 in PBMCs [14]. However, in our 
experimental setup we were unable to detect any effect of IL-10 on the virus-
induced IL-6 and IL-8 release and further studies are warranted to unravel the 
underlying mechanisms of the IFNs-related inhibition of IL-6/8 release. 
Alternatively, IL-1β is a potent inducer of IL-6 and IL-8 [28,29]. Activated 
macrophages are among the major producers of IL-1β [53] and in co-culture with 
A549 the release of IL-1β by THP1 monocyte/macrophages is enhanced [23]. And 
although different studies have suggested that type-I IFNs are also involved in the 
activation of the inflammasome and the subsequent release of IL-1β [27,54,55], the 
role of IFNs in the induction of IL-1β is not completely resolved. Guarda and 
colleagues, for example, demonstrated that type-I IFNs might also prevent the 
release of IL-1β through inhibition of inflammasome activation [56] and this 
discrepancy might be due to the differential activation of different types of 
inflammasomes [57]. In the present study, we also examined the role of IL-1β as 
mediator in the release of IL-6/8 following IFN stimulation of the co-cultures. 
Although we could not detect IL-1β at the protein level, the expression of IL-1β 
mRNA was significantly increased after treatment with either IFN-λ1 or IFN-β. This 
suggests a possible involvement of IL-1β in the release of IL-6 and IL-8 which was 
confirmed by the partial inhibition of the IFN-induced IL-6/8 release in the presence 
of an IL-1 receptor antagonist (IL-1RA). However, since IL-1RA blocks the receptors 
for both IL-1β and IL-1α, specific involvement of either of the two types of IL-1 
cannot be differentiated from these data. Moreover, since the release of IL-6 and 
IL-8 was only partially inhibited by IL-1RA, most likely there are also other 
mediators as well involved along with either IL-1β or IL-1α. 
Summarizing, in the present study we expanded our earlier findings and 
demonstrated that the protective effects of prophylactic treatment with either IFN-
β or IFN-λ1 are not only effective in mono-cultures of epithelial cells or 
macrophages, but also in more complex systems like the co-cultures. Additionally, 
we demonstrated that pretreatment with either of the IFNs significantly prevented 
the release of massive amounts of the pro-inflammatory cytokines IL-6 and IL-8 in 
the co-cultures following RSV infections. Since it is assumed that excessive 
inflammation following viral infections is an important contributor to the initiation 
and severity of acute exacerbations, this finding may have future clinical 
significance. Thus, in conclusion, these data provide further arguments that 
exogenous IFNs could be beneficial to prevent the viral infections and 
exacerbations. Still, additional in vitro and in vivo studies are warranted to evaluate 
Chapter 3                                                                                           Inflammatory response 
Page | 81  
 
the physiological significance and relevance of administration of exogenous IFNs 
with virus induced exacerbations in chronic respiratory diseases.             
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Table Supplementary. Primers used for mRNA expression analysis 
Gene             Primer sequences (5’-3’) 
RSV forward 
reverse 
TTTCCACAATATYTAAGTGTCAA 
TCATCWCCATACTTTTCTGTTA 
IL-8  
            
forward   
reverse 
TTTTGCCAAGGAGTGCTAAAGA 
AACCCTCTGCACCCAGTTTTC 
IL-6            
  
forward   
reverse 
AACAACCTGAACCTTCCAAAGATG 
CCAACTCCAAAAGACCAGTGATGAT 
IL-1β                                  
 
forward                                                               
reverse                      
TCGGAGATTCGTAGCTGGAT 
CAGCCAATCTTCATTGCTCA 
IL-10                                                 
 
forward                                                        
reverse   
TACGGCGCTGTCATCGATTT 
TAGAGTCGCCACCCTGATGT 
β-actin                      
  
forward                                                 
reverse              
TGGAGAAATCTGGCACCAC   
GAGGCGTACAGGGATAGCAC 
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Abstract 
Background 
Previously, it has been demonstrated that patients with chronic obstructive 
pulmonary disease (COPD) and asthma display an impaired immune response 
towards viral infections of the respiratory tract, thereby rendering them more 
susceptible for virus-induced acute exacerbations. In particular the production of 
interferons (IFNs), seems to be impaired in these patients, perhaps because of 
prolonged cigarette smoking. Prophylactic treatment with exogenous IFNs might be 
an effective way to restore this impaired immune response. However, since a 
considerable number of COPD and also asthma patients are still active smokers, the 
protective effect of exogenous IFN treatment might be limited in these patients. 
Yet, whether cigarette smoke attenuates the effects of exogenous IFNs treatment 
is not clear. In this in vitro study we investigated whether respiratory epithelial cells 
are still protected against rhinovirus infection by prophylactic IFN-β treatment 
despite exposure to cigarette smoke extracts (CSE). 
Methods 
Type-II like epithelial cells (A549 cell line) were first treated with different 
concentrations of CSE for 6h and then treated with IFN-β (100 IU/ml) for another 
18h. To determine the effect of CSE on the protective effect of IFN-β against viral 
infection, cells were infected with human rhinovirus 1B (HRV1B) for 1h and 
incubated further for another 24h. Expression of pattern recognition receptors 
(PRRs: involved in viral recognition), IFN stimulated genes (ISGs: involved in 
antiviral response) and viral RNA were determined with qPCR.   
Results 
CSE didn’t have a pronounced effect on the basal mRNA expression of various PRRs 
and ISGs. Furthermore, CSE exposure also barely affected the IFN-β-induced mRNA 
expression of PRRs and ISGs. Alternatively, both CSE-exposed control and IFN-β-
pretreated cells showed higher viral titers than non-CSE-exposed control or 
pretreated cells suggesting a higher susceptibility of these CSE-exposed cells for 
viral infections. Nevertheless, cells pretreated with IFN-β were still markedly 
protected against viral infection irrespective of CSE exposure.  
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Conclusion 
These data show that CSE slightly decrease the ability of IFN-β to inhibit viral 
replication. Nonetheless, cells were still strongly protected by IFN-β against viral 
infection which indicates that prophylactic treatment with IFNs might be beneficial 
even in smokers.    
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Introduction 
 
Viral infections are considered as the most important triggers for acute 
exacerbations (AEs) in COPD and asthma patients [1-5]. Different studies have 
shown that COPD and asthmatics are more predisposed to develop severe effects 
of viral infections of respiratory tract leading to AEs. For instance, Hurst and 
colleagues have shown that frequency of acquisition of common colds is 
significantly increased in COPD patients who experience frequent AEs [6]. Similarly, 
in several in vitro studies an increased viral replication has been observed in 
bronchial epithelial cells from asthmatics and COPD patients [7,8]. Recently it has 
been reported that an impairment of innate antiviral immune response system may 
be responsible for the increase susceptibility of COPD and asthma patients to 
develop virus-induced AEs. More precisely, in both types of patients the production 
of both antiviral type I and III interferons (IFN) by epithelial and immune cells 
seems to be compromised [8-10].  
Although the exact underlying causes of this impaired IFN production 
remains to be elucidated, it has been shown that cigarette smoke - apart from 
increasing the inflammation itself - also affects several aspects involved in the first 
line of defense within the airway. For example, cigarette smoke exposure results in 
impaired mucociliary clearance and enhanced permeability of the airway 
epithelium [11-13]. Moreover, it has been reported that cigarette smoke impairs 
the type I IFN production by different cell types [14,15]. Taken together, this 
suggests that exposure to cigarette smoke may significantly increase the risk for 
respiratory viral infections.  
Previously, we and others have demonstrated that even at low 
concentrations exogenously added IFN-β is well able to protect epithelial cells 
against subsequent rhinovirus infections [16]. This protective effect was most likely 
mediated by the strong increase in the expression of various well-known antiviral 
proteins like Interferon-Stimulated-Gene 15 (ISG15) and myxovirus resistance 1 
(MX1) following IFN-β treatment of airway epithelial cells. This suggests that for 
instance intranasal application of a low dose IFN-β may create an antiviral 
environment in susceptible respiratory patients and may as such be useful for 
prophylactic treatment against virus-induced exacerbations.  
However, one pitfall might be that a significant number of COPD and 
asthma patients, despite a strong medical advice, continue smoking [17-19]. Since 
cigarette smoke has been shown to impair the antiviral response in epithelial cells 
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[14,15], the protective effects of IFN-β treatment may be compromised by 
cigarette smoke and limit the prophylactic effect of such a treatment. Yet in the 
present paper we demonstrate that, although high concentrations of cigarette 
smoke extract indeed impair the basal as well as the IFN-β-induced antiviral 
response, the protective effect of IFN-β treatment is sufficiently maintained and 
epithelial cells exposed to cigarette smoke extract are still strongly protected 
against rhinovirus infections. 
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Materials and methods 
Cell culture 
The A549 alveolar type-II like cells (ATCC CCL-185) were cultured in RPMI 1640 
medium (Gibco, life technologies NY, USA) supplemented with 10% heat-
inactivated fetal calf serum (FSC, Lonza , Verviers, Belgium) at 37ºC/5% CO2.  
Human lung fibroblast cells (MRC5, ATCC CCL-171) were cultured in Minimal 
Essential medium (EMEM 1X, Gibco, life technologies NY, USA) supplemented with 
10% FCS, non-essential amino acids (MP Biomedicals, Solon, Ohio, USA), and L-
glutamine (2 mmol/L). Cells were incubated at 37
o
C/5% CO2. 
Virus culture 
Human rhinovirus 1B (HRV1B) was purchased from American Type Culture 
Collection (ATCC, VR-1645). Viral stocks were generated in MRC-5 cells as 
previously described [16]. In brief, confluent monolayers of MRC-5 cells were 
infected with HRV1B at multiplicity of infection of 1 (MOI-1) for 1h at 33
o
C. After 
infection cells were further incubated at 33
o
C until 100% cytopathogenic effect 
(CPE) was attained. Next, cell debris was removed by centrifugation and viral titers 
were determined with 50% tissue culture infectivity dose (TCID50) assay. 
Cigarette smoke extracts 
Cigarette smoke extracts (CSE) were prepared freshly every time before use, by 
combusting a 3R4F research cigarette (without filter, University of Kentucky) using 
a vacuum/pressure pump (Model No. 7015; Cole-Parmer, Chicago, IL) at constant 
speed. Main stream cigarette smoke was bubbled through 2ml of sterile PBS. To 
remove bacteria and large smoke particles, the resulting suspension was 
subsequently filtered with a 0.2 μm pore Acrodisk
 
filter (Pall Corporation; 
Newquay, Cornwall, UK). Optical density (ΔOD) at 320-540 nm of this suspension 
was monitored using an ELISA reader. Suspensions with a ΔOD close to 1 (0.9-1.1) 
were considered to be 100% CSE. All cigarette smoke extracts were used within 30 
minutes of preparation.  
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Determination of cytotoxicity of CSE 
Before stimulating the cells with CSE for actual experiments, effect of CSE on the 
viability of cells was determined with a colorimetric thiazolyl blue tetrazolium 
bromide (MTT) (Sigma-Aldrich, St. Louis, MO, USA) assay as described previously 
[16]. Briefly, A549 cells were seeded in 96-wells tissue culture plates and treated 
with different concentrations of CSE for 24h. Afterwards the MTT assay was 
performed according to manufacturer’s instructions. The percentage of metabolic 
activity of exposed A549 cells was calculated by comparing to non-exposed controls 
(absorbance exposed/ absorbance non-exposed x 100%). 
Stimulation of A549 cells with CSE 
To investigate the influence of CSE on the basal expression of various intracellular 
double-stranded RNA pattern recognition receptors (PRR), A549 cells were 
propagated in 24-wells tissue culture plates (Becton Dickinson, NJ, USA) until 100% 
confluency was reached and subsequently treated with different concentrations of 
CSE (0%, 2.5%, 5,0%, and 7.5% ) diluted in RPMI1640 with 2% FCS. After 6h of CSE 
stimulation, the cell layer was washed with PBS and cells were lysed by adding 350 
μl of RLT lysis buffer (RNeasy Mini Kit, Qiagen) and stored at -80
o
C until further 
processing. 
Next, we determined the effect of CSE on the IFN-β-induced up-regulation 
of different antiviral proteins as observed in earlier experiments. Again, A549 cells 
were initially stimulated with CSE (0%, 2.5% and 7.5%) for 6 hours and then treated 
with IFN-β (100 IU/ml) for 18 hours in the presence of CSE extract. Finally, cells 
were collected in RTL lysis buffer and stored at -80
o
C until further processing. 
HRV infection of CSE-stimulated IFN-β treated A549 cells 
To determine whether CSE exposure affects the protective antiviral effect 
mediated by IFN-β exposure, cells were treated with CSE (6h) and IFN-β (18h) as 
described before. Then, the supernatant of each well was removed and preserved 
at 33
o
C for later use. Then cells were washed twice with PBS, and infected with 
HRV1B (MOI=1; RPMI 1640, 2% FCS) for 1 hour at 33
o
C. After infection, the 
supernatant was removed and cells were washed three times with PBS, and 
incubated for another 24h at 33
o
C with the preserved medium (containing CSE and 
IFN-β). Lastly, cells were lysed and RNA was isolated as described above.  
Chapter 4                                                             Effect of CSE on antiviral ability of IFN-β 
Page | 94  
 
Plasmid construction and generation of standard curves 
In order to determine viral RNA copy numbers present in the cells, viral RNA 
fragments were in vitro transcribed from a plasmid as previously described [20] 
with some modifications. In brief, viral RNA was reverse transcribed (SuperscriptII 
Reverse Transcriptase, Invitrogen, NY, USA) in the presence of HRV primers 
(supplementary table). The resulting cDNA served as template and amplified by 
conventional PCR. The amplified fragments was then cloned into the pGEMT-easy 
vector (Promega, Wisconsin, USA) and sequenced. The plasmid DNA, designated 
p1123, was transcribed in vitro (T7 RNA polymerase, Fermentas). After that the 
obtained RNA was treated with DNAse (DNase I recombinant, RNase free; Roche) 
and quantified with Nanodrop ND-1000. Copies per μl were calculated with 
Avogadro’s number. Serial dilutions of the quantified RNA were used for the 
generation of a standard curves. 
Reverse transcription and qPCR 
RNA was isolated with RNeasy Mini kit (Qiagen, Hilden, Germany) according to 
manufacturer’s instructions. Isolated RNA was first DNase treated with Turbo DNA-
free kit (Ambion, life technologies, NY, USA) and then reverse transcribed with the 
iScript cDNA Synthesis Kit (Bio-Rad, Hercules,CA, USA). Then 2 μl of cDNA was 
amplified in a final volume of 25 μl containing 12,5 μl iQ SYBR Green Supermix (Bio-
Rad) and appropriate primers (supplementary table). Detection was done as 
described previously [21]. Gene expression were normalized to β-actin levels and 
expression was expressed using the 2
-ΔCt
 method [22]. For quantification of HRV 
RNA copies, standard curves were generated for every qPCR. 
Statistical analysis 
The overall significance of the experimental effect was determined by Kruskal-
Wallis tests and the differences between multiple groups were analyzed by Mann-
Whitney test. Values of p < 0.05 were considered statistically significant. Data are 
expressed as mean ± SEM.  
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Results 
Effect of CSE on the viability of cells 
Since we aimed to use a range of CSE concentrations without any significant effect 
on the viability of cells, metabolic activity of cells was determined by MTT assay 
after treatment with different concentrations of CSE. In our experimental settings 
the use of CSE concentrations up to 7.5% had no significant effect on the viability of 
cells when compared to untreated cells (supplementary figure). Thus, to treat the 
cells with CSE for actual experiments we used a range of CSE concentrations with 
maximum concentration of 7.5%. 
Effect of CSE on mRNA expression of PRRs and ISGs 
Initially, we investigated the effect of CSE on the basal expression of different 
dsRNA PRR’s involved in viral recognition. Apart from a small, though significant up-
regulation of the TLR3 mRNA expression, incubation for 6 h in the presence of 
either 2.5, 5 or 7.5% CSE had no significant effect on the expression of either MDA5 
or RIG-I mRNA (Figure 1A-C).  
 
 
Figure 1. CSE does not affect the basal expression of PRR and ISGs: A549 were stimulated with different 
concentrations of CSE for 6h and afterwards cells were collected in lysis buffer. mRNA expression of RIG-
1 (A), MDA5 (B), TLR3 (C), ISG15 (D), MX1 (E) and PKR (F) genes was determined by qPCR. *, p<0.05 
Control vs rest of the conditions. 
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Moreover, we examined the effect of CSE on the basal mRNA expression of 
different antiviral genes. In line with the PRR’s, no significant effects of CSE on the 
basal expression levels of ISG15 or MX1 were observed. However, a small, though 
significant and dose dependent increase in the expression of protein kinase R (PKR) 
was observed (Figure 1D-F). 
Exogenous IFN-β induces a strong antiviral state in A549  
Previously we have demonstrated that the expression of various antiviral genes 
was dramatically enhanced when cells were treated with IFN-β [16]. Here we 
confirm these results as in particular the mRNA expression of both ISG15 and MX1, 
and to a lesser extent PKR, was markedly increased when cells were treated for 18h 
with 100 IU of IFN-β (Figure 2A). Also, the mRNA expression of the PRRs was 
significantly enhanced when cells were treated with IFN-β (Figure 2B). These data 
confirm observations by us and others that exogenous IFN-β induces a strong 
antiviral condition in epithelial cells of the respiratory tract [8,16,23]. 
 
 
Figure 2. Exogenous IFN-β significantly enhances the expression of PRR and ISGs: A549 were 
stimulated with 100 IU/ml of IFN-β for 18h and afterwards cells were collected in lysis buffer. mRNA 
expression of various ISGs (A) and PRRs (B) genes was determined by qPCR. *, p<0.05 Control vs IFN-β. 
Effect of CSE on exogenous IFN-β induced expression of PRRs and ISGs 
Although CSE barely affected the basal mRNA expression of various dsRNA PRRs, it 
cannot be excluded that exposure to CSE impairs the IFN-β-dependent protective 
antiviral condition in epithelial cells. Therefore we tested the mRNA expression of 
the aforementioned antiviral genes and PRRs in A549 cells which were exposed to 
CSE for 6h before being treated with IFN-β. Yet, the IFN-β-induced up-regulation of 
almost all antiviral genes and PRRs was barely affected by prior exposure to CSE. 
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Even at the highest CSE concentration (7.5%) only the expression of RIG-I and MX1 
was significantly diminished by CSE (Figure 3). This suggests that the protective 
antiviral effect of exogenous IFN-β might be maintained even in smokers. 
 
 
Figure 3. CSE barely affects the induction of PRR and ISGs by exogenous IFN-β: A549 were first exposed 
to different concentrations of CSE for 6h and then stimulated with 100 IU/ml of IFN-β for another 18h. 
After that, cells were collected in lysis buffer and analyzed further to determine the mRNA expression of 
various PRR and ISGs genes was determined by qPCR. *, p<0.05 Control vs rest of the conditions. 
Effect of CSE on the IFN-β inhibited viral replication 
To test whether the antiviral effect is indeed maintained when cells are pre-
exposed to CSE, we infected CSE-exposed A549 cells with a human rhinovirus 
(HRV1B). Previously, we have demonstrated that IFN-β pretreated cells were 
markedly protected against HRV1B infection [16]. In figure 4A we now show that, 
despite exposure to concentrations up to 7.5% CSE, IFN-β-treated cells are still 
highly protected from HRV1B infection when compared to non-treated A549 cells. 
Nevertheless, although cells were protected from HRV1B infection when compared 
to non-treated controls, this protective effect was significantly and dose-
dependently impaired within the CSE-exposed group, which confirms earlier 
observations that CSE affects the innate antiviral response in respiratory epithelial 
cells (Figure 4B). 
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Figure 4. Even CSE treated cells are strongly protected by exogenous IFN-β against viral infection: 
A549 were first exposed to different concentrations of CSE for 6h and then stimulated with 100 IU/ml of 
IFN-β for another 18h. After that CSE + IFN-β containing medium was collected and preserved at 33 oC 
and cells were infected with HRV1B for 1h. Afterwards cells were washed with PBS and preserved 
medium was added again on the cells. Next cells were incubated for another 24h and collected in lysis 
buffer and analyzed further to determine the viral copies by qPCR. *, p<0.05 Control vs IFN-β. # p<0.05 
between indicated conditions 
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Discussion 
In the present study we determined the effects CSE on the expression of various 
PRRs and ISGs involved in the recognition of HRV and antiviral signaling. Also, the 
efficacy of exogenous IFN-β to protect airway epithelial cells against HRV1B 
infection in the presence of CSE was determined. Our data show that CSE barely 
affects the expression of different PRRs and ISGs at baseline or after the 
stimulation with IFN-β. Moreover, although the inhibition of viral replication by 
IFN-β was slightly less in CSE-treated cells, the protective effect was still 
pronounced and efficacious as compared to non-IFN-β-treated cells.  
Viral infections of the respiratory tract are the main cause of AEs in 
asthma and COPD. In particular HRV has been associated with a high incidence of 
virus-related AE’s [1-5]. Effective clearance of viral infections in the respiratory 
tract largely depends on the fast recognition of invading viral particles 
predominantly by epithelial cells [24]. Detection of HRV for example requires the 
presence of double-stranded RNA pattern recognition receptors like TLR3 and 
MDA5 [25-27]. Also RIG-I might be involved although conflicting data have been 
published [27-29]. Activation of these receptors evokes a cascade of intracellular 
signaling events resulting in the release of the antiviral type I/III IFN’s. Subsequently 
the expression of a variety of antiviral ISG’s is initiated, which all contribute to the 
antiviral resistance in cells [30]. Consequently, impairment of these systems may 
severely affect the defense against viral infections. Such impairment may result 
from chronic cigarette smoking as it has been shown repeatedly that cigarette 
smoke is able to affect this antiviral response. For example, the release of CXCL10 
and CCL5 by primary human bronchial epithelial cells or BEAS-2B in response to 
HRV16 was significantly inhibited by cigarette smoke extract [31,32]. Smoking is big 
risk factor for the development and progression of COPD [18,19]. Similarly, among 
asthmatics 25-30% are current smokers [17] and in these patients HRV-induced 
exacerbations are usually more severe and last longer when compared to non-
smokers [33]. Thus, apart from the fact that it prevents loss of lung function and 
reduces morbidity and mortality among patients with chronic respiratory diseases 
[34,35], smoking cessation is also beneficial to restore the respiratory immune 
response and control the incidence of AEs. However, smoking cessation can be 
difficult to achieve, especially among those with higher nicotine dependence 
[36,37]. 
Previously, we and others have demonstrated that exogenous application 
of IFN-β might be an effective way to prevent HRV infections and subsequent AEs. 
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In particular this might be beneficial for patients with chronic respiratory diseases 
who are not able to quit smoking, and in whom the innate immune defense may be 
permanently disturbed as a consequence of their smoking behavior. Here we have 
now extended our earlier observations to show that CSE-exposed epithelial cells 
are still markedly protected against HRV infections. Nevertheless, both under basal 
conditions as well as in IFN-β treated cells an impaired antiviral defense mechanism 
was observed as higher viral load were found in CSE treated cells when compared 
to control cells. Interestingly, however, we didn’t observe marked differences in 
the expression of various PRRs or ISGs under basal conditions when cells were 
exposed to CSE only. This is in accordance with recent data published by Proud et 
al. who recently by gene array analyses demonstrated that CSE had no dramatic 
effects on the expression of various antiviral or PRR genes in airway epithelial cells 
[38]. Alternatively, in the presence of CSE the expression of HRV-induced genes 
associated with various functions including viral defenses, inflammation and airway 
remodeling was significantly diminished. And although we didn’t study the direct 
effects of CSE on HRV-induced expression of these antiviral genes, the observation 
that viral replication was more pronounced in CSE-exposed epithelial cells suggests 
that also in our hands CSE affected the antiviral response in untreated cells. Since 
many of the antiviral genes are so-called Interferon-Stimulated genes (ISG), it has 
been speculated that this impairment is a consequence of a reduction in the 
amount of IFNs produced upon infection. The exact nature of this diminished IFN 
release is still unclear but previous report have shown that exposure to cigarette 
smoke significantly affected the release of IFN and other cytokines involved in 
antiviral immunity [14,15]. However in the study by Proud, IFN-λ1 levels were 
unaffected while IFN-β levels were below the detection limit. Although HRV 
infections have been shown to result in the pronounced release of IFN-β by 
infected airway epithelial cells [29] this has been questioned by others [39]. Also 
data from our lab could not reveal clear evidence for the production of IFN-β by 
epithelial cells following HRV infections [16]. Based on this it seems unlikely that a 
compromised IFN production following smoke exposure is the underlying 
mechanisms for the impaired expression of the antiviral genes. This is also 
supported by our finding that CSE hardly affected the mRNA expression of the 
different ISGs and PRRs in IFN-β-treated cells; only at the maximum concentration 
of CSE (7.5%) the expression of RIG-1 and MX1 was slightly diminished. Taken 
together, these data imply that the CSE-mediated impairment of HRV-induced 
genes is not mediated by manipulation of IFN-dependent effects. 
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The main goal of the present study was to evaluate whether CSE 
negatively affected the protection by exogenous IFN-β against infections with HRV. 
HRVs, which in healthy humans usually only cause a harmless common cold, are 
frequently found in exacerbating asthma and COPD patients. In these patients, 
perhaps because of chronic smoking, lung epithelial cells as well as alveolar 
macrophages produce substantially less type I/III interferons in response to viral 
infections resulting in more severe lower respiratory symptoms and higher viral 
loads [8,9]. Furthermore, not only the release of IFN, but also the antiviral effects 
of exogenous IFN have been shown to be impaired in CSE-treated fibroblasts 
[15,40]. In line with this, in the present study we also found that CSE treatment 
reduced the protective effect of IFN-β against viral infection in epithelial cells as 
HRV copy numbers were significantly augmented in CSE-treated cells. As already 
stated, this is unlikely that this slight decline in protective effect of exogenous IFN-β 
was due to alterations in the expression PRRs or ISGs as only a small (though 
significant) decrease in the expression of RIG-I and MX-1 was observed. 
Alternatively, this CSE-induced effect might be due to the effect of CSE on the 
expression of type-I IFN receptors which have been shown to be down regulated by 
CSE treatment in fibroblasts [40]. Despite this small impairment in the protective 
effect of IFN-β in CSE-treated cells, viral replication was still dramatically reduced in 
CSE+IFN-β cells when compared to non-IFN-β-treated cells. This is also supported 
by the high expression levels of ISGs which indicate that despite CSE treatment cells 
were still in a pronounced antiviral state.  
In conclusion, our data shows that, despite a higher susceptibility of CSE-
exposed cells for HRV infections, CSE had no dramatic effect on the protective 
antiviral effect of exogenous IFN-β in airway epithelial cells. This suggests that even 
in chronic smokers exogenous IFN-β could be beneficial to prevent the viral 
infections and ultimately AEs. 
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Supplementary Figure: Toxicity of CSE in A549 cells. 
 
A549 were treated with different concentrations of CSE for 24h. Next metabolic activity of CSE-treated 
and non-treated cells was determined by MTT assay and compared to each other. *, p<0.05 Control vs 
different CSE concentrations. 
 
Supplementary table . Primers used for mRNA expression analysis 
Gene               Primer sequences (5’-3’) 
HRV forward 
reverse 
TGGACAGGGTGTGAAGAGC 
CAAAGTAGTCGGTCCCATCC 
ISG15  
            
forward   
reverse 
GGTGGTGGACAAGTGCGATG 
CGAAGGTCAGCCAGAACAGG 
Mx1  
            
forward  
reverse 
GGACATCGCCACCACAGAGG 
TCCGCACCACATCCACAACC 
RIG-1                                  
 
forward                                                               
reverse                      
ACTCTGGTTGCCAAATCCAC 
TGGAAGGGATCAGCAAAGAG 
PKR                                                 
 
forward                                                          
reverse   
TGGCGGTCTTCAGAATCAACATC 
CAGCCATTTCTTCTTCCCGTATCC 
MDA5                                                 
 
forward                                                       
reverse   
CGCAAAGAACGTGTTTGTGCC 
CACCACCCTCATCACTATCA 
TLR3                   
  
forward                                                 
reverse              
CCTGGTTTGTTAATTGGATTAACGA 
TGAGGTGGAGTGTTGCAAAGG 
β-actin                      
  
forward                                                 
reverse              
TGGAGAAATCTGGCACCAC   
GAGGCGTACAGGGATAGCAC 
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Abstract 
Background 
Co-infections are common in COPD patients and it has been speculated that 
unrelated pathogens affect the susceptibility to others or synergistically augment 
the inflammatory reaction in the lungs. For example, non-typeable Haemophilus 
influenzae (NTHI), a common colonizer of COPD lungs, is able to up-regulate the 
cellular receptor Intercellular Adhesion Molecule-1 (ICAM-1) which is being used by 
the major group human rhinoviruses (HRV) for cellular adherence. Yet, the effect of 
NTHI on the replication of viruses, including major group HRV, is not clear. In this 
study, the effect of heat-inactivated NTHI (Hi-NTHI) on replication of HRV16 (major 
group), HRV1B (minor group) and respiratory syncytial virus (RSV) was evaluated in 
a bronchial epithelial cell line (BEAS-2B). Further, the effect of Hi-NTHI on the 
inflammatory response of cells upon subsequent viral infection was examined. 
Methods 
BEAS-2B were pre-treated with Hi-NTHI for 24h and then infected for 10 minutes 
with HRV16, HRV1B or RSV at a multiplicity of infection of 10. Next, cells and media 
were collected after 2, 24 and 48h. Viral copy numbers were determined by qPCR 
and the concentrations of the inflammatory cytokines IL-6 and IL-8 in culture 
supernatants were assessed by ELISA.  
Results 
Pre-treatment with Hi-NTHI significantly increased the expression of ICAM-1, 
leading to increased numbers of HRV16 RNA copies at all-time points. Likewise, in 
Hi-NTHI pretreated cells the numbers of RSV and HRV1B RNA copies were 
augmented at 24 and 48h, but not 2h post-infection. However, the percentage 
increase in the viral RNA copies for RSV and HRV1B between Hi-NTHI pre-treated 
and non-Hi-NTHI pre-treated cells was far less than for HRV16. Furthermore, 
production of interleukin-6 and IL-8 was synergistically increased in cells pre-
treated with Hi-NTHI after RSV infection. 
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Conclusions 
Hi-NTHI pre-treatment significantly enhances the replication of HRV16, HRV1B and 
RSV in BEAS-2B cells. Yet, the effect was most pronounced for major group HRV16, 
most likely due to increased initial binding/entrance of HRV16 to the cells because 
of the increased expression of ICAM-1. Furthermore, Hi-NTHI pre-treatment 
facilitated the production of inflammatory cytokines in response to subsequent RSV 
infection, suggesting that a pre-existing bacterial infection might exaggerates the 
inflammatory response when cells are additionally infected by a virus. 
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Introduction 
 
Human rhinoviruses (HRVs) are members of Picornaviridae family. They are 
positive-sense, single-stranded RNA viruses with more than 100 antigenically 
distinct serotypes [1,2]. HRVs infect the upper respiratory tract of healthy 
individuals and are responsible for the majority of common colds. Although these 
common colds are usually benign and self-limiting, they lead to considerable 
economic burden in terms of medical visits and work loss [3-5]. Moreover, in 
patients with underlying chronic respiratory diseases like chronic obstructive 
pulmonary disease (COPD), HRV infections result in more severe lower respiratory 
tract symptoms including acute exacerbations [6,7]. 
Based on their usage of cell surface receptors, HRV serotypes are classified 
either as minor or major group HRVs. While the minor group HRVs use the low-
density lipoprotein (LDL) receptors, the major group HRVs, which are about 90% of 
the known serotypes, use the intercellular adhesion molecule-1 (ICAM-1) as their 
receptor to enter the cytoplasm of cells [2,8,9]. 
Also bacterial infections can initiate acute exacerbations in patients with 
chronic respiratory diseases [10-12]. Although the human upper respiratory tract is 
a reservoir of different commensal and potential pathogenic bacteria [13], 
infections of the lower respiratory tract on the other hand frequently result in 
severe acute exacerbations [11]. Among these bacteria, non-typeable Haemophilus 
influenzae (NTHI) is frequently isolated from COPD patients, both when clinically 
stable or during acute exacerbations [14-17].  
Apart from the fact that both bacterial and viral microorganisms can 
independently cause respiratory infections, it has previously been established that 
an infection with one pathogen can create a conducive environment for an 
infection with another unrelated pathogen [18-22]. It has been described 
extensively that viral infections promote the susceptibility to subsequent bacterial 
infections. For example, trans-epithelial migration of bacteria is significantly 
enhanced because of a disrupted epithelial barrier following a viral infection 
[23,24]. Also, enhanced bacterial adhesion and impaired antibacterial immune 
responses following earlier viral infections have been reported [25-30]. 
Alternatively, the effects of bacterial colonization on the susceptibility for viral 
infections have been studied less extensively. Interestingly, earlier studies have 
shown that infections with NTHI increase the expression of ICAM-1 [19,31]. Thus, 
being the single cellular receptor for major group HRVs, increased ICAM-1 
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expression could lead to increased binding and replication of this type of HRV [32-
34]. Indeed, previously it has been demonstrated that NTHI infection enhances the 
binding of major group HRV to airway epithelial cells. Furthermore, the release of 
HRV-induced chemokines is also increased by NTHI infected cells [19]. Yet, it 
remains to be determined whether this only results in enhanced binding of the 
virus to the cells or also augments viral replication. Moreover, it needs to be 
established whether the enhanced sensitivity is solely due to an increased 
expression of ICAM-1 making the cells more sensitive to viruses which use the 
ICAM-1 receptor for attachment, like the major group of HRV, or whether it is a 
general effect rendering the cells more sensitive to any other viral infection. To 
understand and differentiate this in a more clear way, we evaluated the effect of 
NTHI treatment on the replication of HRV16 (major group HRV), HRV1B (minor 
group HRV) and respiratory syncytial virus (RSV) in the bronchial epithelial cell line 
BEAS-2B. Furthermore, we hypothesized that co-infections may synergistically 
enhance the release of inflammatory mediators and contribute as such to the 
initiation of acute exacerbations and progression of chronic airway diseases. To 
study this we measured the production of two important inflammatory mediators 
(interleukin-6 (IL-6) and interleukin-8 (IL-8)) by NTHI-pretreated cells either in the 
presence or absence of viral infections. 
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Materials and Methods 
Cell Culture 
Human bronchial epithelial cells (BEAS-2B, ATCC CRL-9609) were maintained in pre-
coated cell culture flasks (T-75, Greiner bio-one GmbH, Frickenhausen, Germany) in 
RPMI 1640 medium (Gibco, life technologies, NY, USA), supplemented with 10% 
fetal calf serum (FCS) (Lonza, Verviers, Belgium) and incubated at 37
o
C/5% CO2. 
Flasks were pre-coated with LHC Basal medium (Gibco, life technologies, NY, USA) 
supplemented with 0.001% Human natural fibronectin (BD Bioscience, California, 
USA), 0.003% bovine collagen type I (Gibco, life technologies, NY, USA), and 0.001% 
bovine serum albumin (Boehringer Mannheim GmbH, Mannheim, Germany).  
Human lung fibroblast cells (MRC-5, ATCC CCL-171) were maintained in 
Minimal Essential medium (MEM 1X, Gibco, life technologies, NY, USA). Medium 
was supplemented with L-glutamine (2 mmol/L), non-essential amino acids (MP 
Biomedicals, Solon, Ohio, USA), and 10% FCS (Lonza). Cells were incubated at 37
o
C 
in 5% CO2.  
Bacterial preparation and heat inactivation 
The NTHI strain (ATCC 49247) was grown on vitalex supplemented chocolate blood 
agar plates (Oxoid, Wesel, Germany). In order to prevent bacterial overgrowth in 
the cell cultures, bacterial suspensions of 0.5 McFarland (1.5 x 10
8 
cfu/ml) in RPMI 
1640 were heat inactivated at 65
o
C for 30 minutes. After cooling down, 
suspensions were supplemented with 2% FCS and then added to the wells.  
Virus culture 
HRV1B was purchased from American Type Culture Collection (ATCC, VR-1645), 
while HRV16 was a kind gift from the Department of Virology at Erasmus MC 
Rotterdam, the Netherlands. Viral stocks were generated in MRC-5 cells as 
previously described [35]. In brief, cells were grown in culture medium with 2% 
FCS. After infection with virus at multiplicity of infection of 1 (MOI-1) for 1h, cells 
were incubated at 33
o
C until 100% cytopathogenic effect (CPE) was attained. After 
that cell debris was removed by centrifugation. To determine the viral titers, 50% 
tissue culture infectivity dose (TCID50) assay was performed. 
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Respiratory syncytial virus A2 (RSV) was obtained from Dutch Vaccine 
institute. Vero cells were used for the generation of viral stocks. After 2h of 
infection, cells were washed with PBS and incubated further in DMEM with 1% FCS 
until more than 80% CPE was attained. Cell debris was removed by centrifugation 
for 10 minutes at 1000 x g. Virus was subsequently precipitated with polyethylene 
glycol (PEG). Therefore, PEG stock solution (50% PEG6000 in 150mM NaCl, 1mM 
EDTA, 6.1 g/L TRIS, pH 7.5) was mixed with virus pool to get 10% PEG (1:5), stirred 
2h at 4C, and then centrifuged 30 minutes at 3000 x g. The pellet was then re-
suspended in PBS + 25% sucrose in 10% of original volume. TCID50 assay was 
performed to determine the viral titers. 
Treatment of cells with heat-inactivated NTHI 
BEAS-2B cells were seeded in 24-well tissue culture plates (Becton Dickinson, NJ, 
USA) at a density of 2x10
5 
cells per well in RPMI 1640 (10% FCS). After 24h, the 
medium was replaced by a 0.5 McFarland suspension of heat-inactivated NTHI (Hi-
NTHI) and cells were incubated for another 24h. 
Virus infection 
After 24h treatment with Hi-NTHI, cells were washed twice with RPMI 1640 (0% 
FCS) and then infected in RPMI 1640 (2% FCS) with HRV16, HRV1B or RSV at MOI-
10 for 10 minutes at 33
o
C (HRV16/1B) or at 37
o
C (RSV). After the infection period, 
cells were washed once with RPMI 1640 (0% FCS) and fresh RPMI 1640 (2% FCS) 
was added to the cells. Next, cells were incubated either at 33
o
C (HRV16 or HRV1B 
infected) or at 37
o
C (RSV infected) for another 2h, 24h and 48h. At each time point, 
cell-free supernatants and cells were collected stored at -80
o
C until further 
analyses.      
Plasmid construction for the generation of standard curves 
In order to prepare a standard curve for determining viral RNA copy numbers, viral 
RNA fragments were in vitro transcribed from a plasmid as previously described 
[36]. Briefly, viral RNA was reverse transcribed (SuperscriptII Reverse Transcriptase, 
Invitrogen, NY, USA) in the presence of HRV or RSV primers (supplementary table). 
The resulting cDNA fragments were then amplified by PCR. The PCR fragments was 
then cloned into the pGEMT-easy vector (Promega, Wisconsin, USA) and 
sequenced. The resulting plasmid DNA, designated p1123 (HRV) and p1092 (RSV), 
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was transcribed in vitro (T7 RNA polymerase, Fermentas). After that the obtained 
RNA was treated with DNAse (DNase I recombinant, RNase free; Roche) and 
quantified with Nanodrop ND-1000. Copies per μl were calculated with Avogadro’s 
number. Serial dilutions of the quantified RNA were used for the generation of a 
standard curves. 
Quantification of viral load in infected cells 
Total RNA was isolated with FATRK 001 (Favorgen Biotech Corporation, Pingtung 
County, Taiwan), according to manufacturer’s instructions. Isolated RNA was then 
DNase treated with Turbo DNA-free kit (Ambion, life technologies, NY, USA) and 
quantified with Nanodrop ND-1000. Next, 1 µg of DNase treated RNA was reverse 
transcribed with the iScript cDNA synthesis kit (Bio-Rad, Hercules, California, USA) 
and quantitative real-time PCR (qPCR) was performed as previously described [37]. 
To determine the actual number of copies of viral RNA standard curves were 
generated for every qPCR. To normalize the gene expression, β-actin levels were 
used. Fold changes were calculated using the 2
-ΔΔCt
 method [38]. 
TCID50  
In order to determine the virus titers, a TCID50 assay was performed as previously 
described [39] with some modifications. Supernatants were collected from infected 
BEAS-2B and serially diluted 1:2 in MEM (1X) containing 2% FCS (Lonza), non-
essential amino acids and L-glutamine (2 mmol/L).  These dilutions were then 
added to confluent layers of MRC-5 cells in 96-well plates. TCID50 was calculated 
according to Spearman-Karber formula.  
Western blot analysis 
Hi-NTHI pre-treated and control BEAS-2B cells were collected in 1 ml of phosphate-
buffered saline and centrifuged. Proteins were extracted from cell pellets with NP-
40 lysis buffer (150 mM NaCl, 1% NP-40 and 50 mM TRIS). Equal volumes of protein 
suspension were loaded onto 10% SDS-polyacrylamide gels and separated with 
electrophoresis. Next, proteins were transferred onto nitrocellulose membranes 
and blocking of unspecific binding sites was performed in 5% dried, non-fat milk, 
dissolved in tris-buffered saline with tween 0.05% (TBS-T). After that, membranes 
were incubated overnight with primary antibodies against ICAM1 (R & D systems, 
Minneapolis, MN, USA) and β-actin (antibodies-online GmbH, Aachen, Germany) at 
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room temperature. Then membranes were incubated with horseradish peroxidase-
conjugated secondary antibodies (R & D systems, Minneapolis, MN, USA) for 1h at 
room temperature. Finally, after washing with TBS-T, proteins were detected by 
using an enhanced chemiluminescence system (Luminoscope, Bio-Rad, Hercules, 
CA, chemiluminescence reagents: Sigma-Aldrich, St. Louis, USA). Quantity one 
software from Bio-Rad was used to calculate the optical density.  
Quantification of IL-6 and IL-8 
To determine the levels of IL-6 and IL-8, an enzyme-linked immunosorbent assay 
was performed according to the manufacturer’s instructions. For IL-6, Human ELISA 
Ready-SET-Go! kits (affymetrix eBioscience, USA) was used, while IL-8 was 
quantified using the Human CXCL8/IL-8 Quantikine ELISA Kit (R & D systems, 
Minneapolis, USA).  
Statistical analyses 
Overall statistical significance was determined by Kruskal-Wallis test and 
differences between the multiple groups were determined by using Mann-Whitney 
test. Data are expressed as mean ± SEM.  
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Results 
Hi-NTHI pre-treatment increases ICAM-1 expression 
In a first set of experiments, we aimed to confirm the increase in the ICAM-1 
expression following Hi-NTHI treatment in our experimental setting. For this, BEAS-
2B cells were treated with Hi-NTHI for 24h and the expression of ICAM-1 was 
determined at both mRNA and protein levels. qPCR (Fig. 1A) and western blot (Fig. 
1B & C) data showed a significant increase in the expression of ICAM-1 in the Hi-
NTHI treated cells as compared to non-treated cells.  
 
 
Effect of Hi-NTHI pre-treatment on HRV16 replication  
As shown above and as demonstrated by others, NTHI increases the expression of 
ICAM-1 by airway epithelial cells, which results in increased binding of major group 
HRV to the cells [19]. However, the effect of NTHI on the subsequent replication of 
major group HRVs is not clear. To determine the effect of NTHI on the viral 
replication, BEAS-2B cells were infected with HRV16 after 24h of treatment with Hi-
NTHI. In order to minimize any potential effect of viral infection itself on the 
expression of ICAM-1, cells were infected just for 10 minutes after which unbound 
Figure 1. Hi-NTHI pre-treatment induce ICAM-
1: Cells were either pre-treated with Hi-NTHI or 
control medium for 24h. After that cells were 
collected to determine the mRNA (A) and 
protein (B & C) expression of ICAM-1. Mann-
Whitney test was applied to determine the 
difference between the groups. * = p<0.05. 
n=5 for figure A and n=4 for figure C. 
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virus was removed and cells were further incubated. Viral RNA copies in the cells 
and infectious viral particles in the supernatants were determined by qPCR and 
TCID50 respectively. 
 
Increased numbers of HRV16 RNA copies in Hi-NTHI pre-treated bronchial epithelial 
cells 
As expected, already after two hours of infection, significantly more viral RNA 
copies were detected in Hi-NTHI pre-treated cells as compared to control cells (Fig. 
2A) indicating enhanced binding and/or entrance of virus into the cells.  Similarly, 
at later time points the viral RNA copies detected in the Hi-NTHI pre-treated cells 
were significantly higher than viral RNA copies detected in virus-infected control 
cells. In both Hi-NTHI pre-treated and control cells, maximal copies numbers were 
detected at 24h post-infection (p.i.). At 48h p.i., however, number of viral RNA 
copies already declined when compared to the 24h p.i. time point in both 
conditions. Yet, in Hi-NTHI pre-treated cells there were still significantly more 
copies than at 2h p.i., whereas in the infected control cells, the number of copies at 
48h p.i. was no longer different from the number of copies detected at 2h p.i. This 
shows that replication of virus was better and lasted longer in Hi-NTHI pretreated 
cells as compared to control cells. 
 
 
Figure 2. Hi-NTHI pre-treatment results in increased HRV16 replication: Hi-NTHI pre-treated and non-
Hi-NTHI pre-treated cells were infected with HRV16 for 10 minutes and incubated further for 2, 24 and 
48h. Both cells and media were collected at all time points. The number of viral mRNA copies was 
determined by qPCR (A) and to determine number of infectious viral particles TCID50 assays was 
performed (B). For figure A, * = p<0.05 between 2h and other time points. # = p<0.05 between Hi-NTHI 
pre-treated and non-Hi-NTHI pretreated conditions at respective time points. For figure B, * = p<0.05 
between Hi-NTHI pre-treated and non-Hi-NTHI pretreated conditions. n=4 
 
Hi-NTHI pre-treatment increases the generation of HRV16 infectious particles  
Next, we evaluated whether the infectious progeny released by Hi-NTHI pre-
treated cells was also augmented. Therefore the number of viral particles was 
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determined in the supernatants by TCID50. Although the overall number of 
infectious viral particles detected was low - perhaps because of the limited time of 
initial infection (10min) – significantly higher numbers of progeny were found in 
the supernatant of infected Hi-NTHI pre-treated cells as compared to infected 
control cells both 24 and 48h after infection (Fig. 2B). These data confirm that pre-
treatment with Hi-NTHI not only results in enhanced binding of viral particles to the 
cells but truly augments the replication of HRV16.  
Effect of Hi-NTHI pre-treatment on HRV1B and RSV replication 
From the results presented above it was not clear whether the observed increase in 
HRV16 replication after Hi-NTHI pre-treatment was solely due to increased binding 
of virus particles to the cells because of enhanced expression of ICAM-1, or 
whether it was a general effect of Hi-NTHI pre-treatment resulting in an increased 
susceptibility of the cells for viral infections. To further unravel this, BEAS-2B cells 
were infected with HRV1B (which uses the LDL receptor for adherence) and RSV 
after Hi-NTHI pre-treatment and viral RNA copy numbers were determined by qPCR 
(Fig. 3A & B). 
 
 
Figure 3. Effect of Hi-NTHI pre-treatment on HRV1B and RSV replication: Hi-NTHI pre-treated and non-
Hi-NTHI pre-treated cells were infected with either HRV1B (A) or RSV (B) for 10 minutes and incubated 
further for 2, 24 and 48h. Cells were collected at all-time points and the number of viral mRNA copies 
was determined by qPCR. * = p<0.05 between 2h and other time points. # = p<0.05 between Hi-NTHI 
pre-treated and non-Hi-NTHI pretreated conditions at respective time points. n=4  
 
In contrast to infection with major group HRV, two hours after the 
infection with HRV1B or RSV the number of viral RNA copies detected in infected 
Hi-NTHI pre-treated and control cells were not significantly different from each 
other. At 24 and 48h, however, Hi-NTHI pretreated cells also contained more 
HRV1B and RSV RNA copies when compared to control cells. Yet, when the increase 
in viral copies was expressed as percentage increase over cells not pre-treated with 
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Hi-NTHI, the increase was significantly higher in cells infected with the major group 
HRV16 (2h:+93%, 24h:+273%, 48h:+413%) when compared to cells infected with 
HRV1B (2h:-30%, 24h:+27%, 48h:+115%) or RSV (2h:-5%, 24h:+81%, 48h:+61%) (Fig. 
4). This indicates that Hi-NTHI pre-treatment especially enhances the susceptibility 
for major group HRVs, most likely through the up-regulation of the ICAM-1 
entrance receptor.  
 
 
Effect of Hi-NTHI pre-treatment on IL-6 and IL-8 production upon subsequent viral 
infection 
Earlier, it has been shown that pre-incubation with HI increases the major group 
HRV39-induced expression of inflammatory mediators (e.g. IL-8). Furthermore, this 
increase was shown to be associated with increased binding of virus to the cells 
[19]. In pursuance of differentiating the effect of Hi-NTHI pre-treatment on the 
production of inflammatory mediators induced by HRV16, HRV1B and RSV, levels of 
two different pro-inflammatory cytokines (IL-6 and IL8) were determined. At 2h 
after pre-treatment of cells with Hi-NTHI, significantly increased levels of both IL-6 
and IL-8 were detected, which further increased over time. Unexpectedly, neither 
HRV16 (Fig. 5A & B) nor HRV1B (Fig. 5C & D) increased the production of IL-6 or IL-8 
by non-Hi-NTHI pre-treated cells at any time point. 
Additionally, no increase in the release of the Hi-NTHI-induced production of IL-6 or 
IL-8 was observed by subsequent infection with either HRV16 or HRV1B. However, 
in contrast to  the HRVs, RSV induced the production of both inflammatory 
mediators. Although no induction of IL-6 was observed after RSV infection of 
control cells at 2h time point, significant levels of IL-6 were detected at 24h time 
point, which further increased at 48h (Fig. 5E). Moreover, RSV infection of Hi-NTHI 
pre-treated cells induced a significantly higher release of IL-6 as compared to 
Figure 4. Relative change in viral 
RNA copies over time: The number 
of RNA copies detected in non-Hi-
NTHI pre-treated cells for particular 
virus at particular time was 
considered 100% and the percentage 
change from this for the respective 
virus at respective time point was 
calculated. * = p<0.05 between 
HRV16 and other viruses (HRV1B and 
RSV) at respective time points. n=4 
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control cells treated with Hi-NTHI or infected with RSV alone. This increase was 
synergistic and was observed at both 24 and 48h time points. Similarly, IL-8 
production was also induced by RSV infection but with delayed onset (Fig. 5F). 
 
 
Figure 5. Effect of Hi-NTHI pre-treatment and subsequent viral infection on IL-6 and IL-8: Hi-NTHI pre-
treated and non-Hi-NTHI pre-treated cells were infected with either HRV16 (A, B), HRV1B (C, D) or RSV 
(E, F) for 10 minutes and incubated further for 2, 24 and 48h. Media were collected at all-time points 
and protein levels of IL-6 (A, C, E) and IL-8 (B, D, F) were determined by ELISA. * = p<0.05 between 
control and other conditions at respective time point. # = p<0.05 between the two indicated conditions. 
n=4 
  
At 24h, the increase in IL-8 levels after RSV infection alone did not achieve 
statistical significance. At 48h, however, a significant increase in IL-8 was observed 
after RSV infection of both control and Hi-NTHI pre-treated cells. Also, HRV and Hi-
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NTHI synergized on the release of IL-8 by the cells. Overall, these data suggest that 
RSV infection in patients colonized by NTHI may experience a more severe 
inflammatory reaction when subsequently infected with RSV than NTHI-free 
patients. 
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Discussion 
 
Bacterial and viral co-infections are common in COPD [40]. Infections with either 
type of pathogen can modulate the host immune responses and enhance the 
susceptibility to subsequent infections with other pathogens [41]. Infections with 
HRV, for example, have been shown to promote secondary bacterial infections, 
including NTHI infection, through different mechanisms [23,27,29,42]. As both HRV 
and NTHI have been shown to be important triggers for exacerbations in COPD 
patients, interactions between both may even result in more severe disease in 
these patients and studying such interactions may help to understand the often 
detrimental effect of respiratory infections in COPD.  
Although it has been demonstrated repeatedly that HRV infections 
facilitate subsequent infections with NTHI [23,29,42], the reverse has been studied 
less intensively. In the present study we evaluated the effects of Hi-NTHI pre-
treatment on the replication and generation of infectious progeny of HRV16, 
HRV1B and RSV in bronchial epithelial cells. Previously, it has been shown that NTHI 
infection increases the expression of ICAM-1 [19,31]. This transmembrane 
glycoprotein is expressed by a variety of cells including epithelial cells. It plays an 
important role in the host immune response through the recruitment of leukocytes 
to the site of inflammation and infection [31,43,44]. Besides the role of ICAM-1 in 
the immune response, this glycoprotein is also exploited by major group HRVs as 
their receptor for the attachment to the cells [8]. Expression of ICAM-1 is regulated 
at transcriptional level and can be induced in response to different stimuli including 
NTHI [31,43] which consequently leads to enhanced viral binding [19]. Yet, it is 
unclear whether this enhanced binding indeed results in enhanced replication and 
shedding of infectious progeny. In line with previous reports, we also found strong 
induction of ICAM-1 after Hi-NTHI pre-treatment, both at mRNA (9.74 fold, p<0.05) 
and protein (4.7 fold, p<0.05) levels (Fig. 1). Concomitantly, there was already a 
significant increase in the number of viral RNA copies of the major group HRV16 in 
Hi-NTHI pre-treated cells at 2h post infection. Moreover, this increase was even 
more pronounced at later time points and, even more importantly, we also found a 
significant increase in the release of infectious viral particles by Hi-NTHI pretreated 
cells. This implies that Hi-NTHI pre-treatment not only results in increased 
adherence of HRV16 but that there is a true effect also on viral replication and 
production of infectious progeny. 
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In contrast to HRV16, no significant difference was observed in the 
number of RNA copies two hours after infection with the minor group HRV1B, 
which utilizes the LDL receptor [45] instead of ICAM-1 for cell entry. At later time 
points only a minor increase was observed in Hi-NTHI pre-treated cells. Similar to 
HRVs, RSV is another important pathogen of the respiratory tract and inducer of 
acute exacerbations in COPD patients [46,47]. Among other different molecules, 
ICAM-1 has also been claimed to be used by RSV as a receptor [48,49]. Yet definite 
validation is lacking [48] and the results in the present study likewise do not firmly 
support a role for ICAM-1 in the adherence of RSV to epithelial cells. No increase of 
RSV RNA copies in the Hi-NTHI pretreated cells were found at 2h post infection, 
while the increase was only moderate at later time points. Together these results 
imply that the observed effect of Hi-NTHI pre-treatment on viral replication is most 
pronounced for the major group HRVs, although we cannot exclude a more general 
effect on the susceptibility of the cells as we also observed a slight though 
significant increase in viral RNA copy numbers in HRV1B- and RSV-infected cells. 
Airway epithelial cells produce different inflammatory mediators in 
response to viral or bacterial infections [50,51]. IL-6 and IL-8 are two important 
inflammatory cytokines and acute exacerbations of COPD have been associated 
with increased levels of these molecules [52,53]. Previously, HRVs, RSV and NTHI 
have been shown to independently induce the production of these inflammatory 
mediators in airways epithelial cells [54-56]. Yet, bacterial and viral co-infections 
can synergistically enhance the inflammatory response of the cells [19,57] and as 
such contribute to the disease severity. In the present study, we could confirm that 
bronchial epithelial cells indeed release both IL-6 and IL-8 in response to Hi-NTHI. 
Moreover, RSV infections also induced the release of both IL-6 and IL-8 in control 
cells and this effect was synergistically enhanced when cells were first pre-treated 
with Hi-NTHI. Surprisingly, however, no significant changes in IL-6 and IL-8 protein 
levels was seen after infection with either HRV16 or HRV1B, irrespective whether 
cells were pre-treated with Hi-NTHI or not. It should however be noted that viral 
RNA copy numbers in the HRV-infected cells were substantially lower than those in 
the RSV infected cells, which may explain the observed difference between the two 
viruses. Nonetheless, at least for RSV, these results demonstrate that co-infections 
may dramatically enhance the inflammatory response and thereby in the long run 
contribute to the induction of acute exacerbations and disease progression.   
Taken together, our data suggest that Hi-NTHI pre-treatment enhances 
the susceptibility of bronchial epithelial cells for viral replication and in particular to 
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infections with major group HRVs, most likely through the up-regulation of ICAM-1 
expression. Furthermore, our data suggest that a viral infection on top of a 
bacterial infection may significantly enhance the production of inflammatory 
mediators. These findings could explain the greater decline of lung function and 
longer hospital stay associated with COPD exacerbations induced by bacterial and 
viral co-infection [40,58] and may give us new opportunities for therapeutic 
strategies to prevent these exacerbations. 
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Supplementary table: Primers used for mRNA expression analysis 
Gene      Primer sequences (5’-3’) 
RV    forward  TGGACAGGGTGTGAAGAGC 
              reverse  CAAAGTAGTCGGTCCCATCC 
RSV              forward  TTTCCACAATATYTAAGTGTCAA 
              reverse  TCATCWCCATACTTTTCTGTTA          
ICAM-1                             forward                 CTGCAGACAGTGACCATC 
              reverse                  GTCCAGTTTCCCGGACAA 
β-actin              forward  TGGAGAAATCTGGCACCAC 
              reverse            GAGGCGTACAGGGATAGCAC 
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General discussion and summary 
 
In this thesis we tested the following 2 original hypotheses: 1) the prophylactic 
treatment with exogenous IFNs is a valuable option to prevent viral infections and 
excessive inflammation of the respiratory tract and 2) H. influenzae infection 
enhances the viral replication and the inflammatory response upon subsequent 
viral infections. 
Viral infections of the respiratory tract are the most frequent cause of 
respiratory illnesses and impose a substantial amount of societal and economic 
burden globally [1]. In healthy individuals the pulmonary immune system most of 
the time efficiently clears these viral infections. However, in individuals with some 
underlying chronic condition the immune system may have become impaired and 
viral infections frequently result in detrimental consequences [2-7]. Chronic 
obstructive pulmonary disease (COPD) and asthma are two examples of such 
chronic inflammatory conditions in which impaired immune responses have been 
observed [5,6,8,9]. Acute exacerbations, which are characterized by acute 
worsening of the respiratory symptoms, are important events in the course of 
these diseases [10,11]. Exacerbations are the major cause of morbidity and 
mortality in asthma and COPD and viral infections are the predominant causes of 
these exacerbations [12,13]. Unfortunately, currently available antiviral therapies 
to prevent virus-induced exacerbations are of limited efficacy [14]. Thus, discovery 
and development of new therapies is an important goal in current antiviral 
research. To address this problem, identification of abnormalities in the immune 
response to viral infections and restoration or protection, if possible through 
external means, could be one option. Also further understanding and identification 
of those factors, which promote viral infections, might be helpful to formulate new 
strategies to prevent or cure viral infections. 
One apparent abnormality in the immune response to viral infections is 
the deficient production of interferons (IFNs) in chronic respiratory diseases like 
asthma and COPD [15,16]. Furthermore, in order to establish successful infection, 
viruses have evolved strategies to evade the immune defense and the extent to 
which these viruses are able to induce disease is mainly due to their ability to 
suppress the production of IFNs [17-21]. Therefore, administration of exogenous 
IFNs could be an approach to prevent virus infections and consequently 
exacerbations. In the present thesis we investigated in various in vitro studies the 
different aspects of treatment of airway cells with exogenous IFNs. Furthermore, 
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human rhinoviruses (HRVs) are considered as the most important inducers of 
exacerbations. It has been suggested that co-infection with bacteria like the non-
typeable Haemophilus influenzae (NTHI), a common colonizer of airways in COPD 
patients, promotes the infections with HRVs. These potential effects of HI on the 
replication of HRV and inflammatory response of airway epithelial cells upon 
subsequent viral infections were also investigated. 
Type I and III interferons: key antiviral mediators  
IFNs constitute the mainstay of the antiviral response of cells. Viral infections are 
identified by cells through different sensors which recognize the virus-associated 
nucleic acid and activate the antiviral signaling pathways [22]. Activation of the 
signaling pathways results in the production and release of IFNs. Released IFNs 
then bind to their receptors on the cell surface which leads to the transcriptional 
induction of interferon stimulated genes (ISGs) [23,24]. Proteins encoded by these 
ISGs exert the antiviral effects through different mechanisms including interference 
with translation, degradation of RNA and interference with virus assembly and 
release [24].  
Although the intrinsic ability of cells to produce IFNs in response to viral 
infection seems impaired in chronic respiratory diseases, there’s evidence that cells 
remain responsive to exogenous IFNs [16,25]. This indicates that deficiencies in the 
antiviral response could perhaps be restored with the administration of exogenous 
IFNs. Even in patients who are not deficient in their IFN production, exogenous 
administration of IFNs might be beneficial to prevent viral infections and 
subsequent consequences. Moreover, in the respiratory tract the local 
administration of IFNs through intranasal sprays or inhalers could help to prevent 
the side effects associated with systemic IFNs treatment [26,27]. In this thesis, we 
investigated the different aspects of treatment of airway cells with exogenous 
type-I IFN (IFN-β) and a member of the more recently discovered type-III IFN family 
(IFN-λ1). 
Antiviral response    
Both IFN-β and IFN-λ1 have antiviral properties. Earlier our lab has shown that IFN-
β -treated airway epithelial cells acquired a long-lasting antiviral state and were 
fairly well protected against subsequent viral infections [28]. However, 
accumulating evidence indicates that type-III IFNs could be more important for 
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mucosal antiviral defense than type-I IFNs [29,30]. Therefore, in chapter 2 we 
evaluated the efficacy of IFN-λ1 to protect the airway epithelial cells against 
infections with the human rhinovirus1B (HRV1B) and compared its efficacy with 
IFN-β. Our data show that similar to IFN-β a single treatment with IFN-λ1 also 
induced a strong long-lasting antiviral state in both the alveolar type II epithelial 
cell line A549 and primary bronchial epithelial cells. These data indicated that like 
IFN-β also IFN-λ1 has strong potential as an antiviral therapeutic. This antiviral state 
induced by both types of IFNs was associated with a markedly enhanced expression 
of interferon stimulated genes (ISGs). Above all, the most important observation of 
this study was that the expression of ISGs was either sustained or even increased 
overtime when cells were treated with IFN-λ1, while the IFN-β-induced ISG 
expression decreased over time. This indicates that the antiviral state induced by 
IFN-λ1 lasts even longer than the one induced by IFN-β. Similar observations have 
been reported earlier by Maher and colleagues who found that activation of STAT1 
and STAT2 after IFN-λ1 treatment in human keratinocyte cell line was sustained 
over the course of 24h as compared to IFN-α-induced activation which was far 
more transient [31]. Overall, our results strongly suggest that, like IFN-β, IFN-λ1 
also has the potential as prophylactic agent to prevent viral infections and its 
protective effect might even last longer than the effect induced by IFN-β. 
Inflammatory response 
Although acute exacerbations in asthma and COPD are triggered by multiple factors 
like allergens, cigarette smoke, respiratory infections etc., airway inflammation is 
the common pathway used by all the different triggers to induce acute 
exacerbations [32-34]. Data shown in chapter 2 and in an earlier study published by 
our lab [28] suggest that a single, local (e.g. intranasal) low dose application of IFNs 
once every few days may be protective against future viral infections of the 
respiratory tract. As such, this may prevent the occurrence of side effects as seen 
frequently throughout repetitive continuous administration in the course of 
exogenous IFNs therapy [27,35]. Furthermore, for the respiratory tract type-III IFNs 
might be a better choice than type-I IFNs because the expression of type-III IFN 
receptors seems restricted mainly to epithelial cells. Yet, whether there’s a direct 
effect of exogenous IFNs on the inflammatory reaction in the airways is not 
completely understood. In chapter 3 we addressed this and evaluated the 
inflammatory response of airway cells to exogenous IFNs.  
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To monitor the inflammatory response of either airway epithelial cells or 
macrophages towards both IFNs, we choose to study the release of both IL-6 and 
IL-8 by both cell types. Both IL-6 and IL-8 are associated with exacerbations in COPD 
[36,37] and play an important role also in pathophysiology and exacerbations of 
asthma [38-41]. Yet, when epithelial cells were stimulated with either IFN-λ1 or 
IFN-β, no release of either cytokine was observed. In contrast to epithelial cells, 
stimulation of THP1-derived macrophages with either IFN-λ1 or IFN-β induced the 
release of significant amounts of IL-8, which suggests that macrophages are more 
sensitive to IFN treatment than epithelial cells. However, in the respiratory tract 
epithelial cells and macrophages (among others) closely interact and respond to 
noxious stimuli in an interactive manner. Also, the response to (potential) 
therapeutic agents like the IFNs might be different in more complex networks. To 
examine this, we also tested the release of both IL-6 and IL-8 in 
macrophage/epithelial cell co-cultures. Indeed, in co-cultures a synergistic increase 
in the release of both IL-6 and IL-8 in response to IFN-λ1 or IFN-β was observed. 
This was the result of complex crosstalk between macrophages and epithelial cells, 
which was partially mediated by IL-1. These data suggest that exogenous 
administration of IFNs may have harmful instead of therapeutic consequences, 
especially in asthma and COPD patients, who already are in a state of permanent 
inflammation [42,43]. However, when co-cultures were infected with RSV, pre-
treatment with either IFN-λ1 or IFN-β markedly reduced the release of IL-6 and IL-
8. Moreover, levels of IFN-λ1- or IFN-β-induced IL-6 and IL-8 were moderate as 
compared to RSV-induced IL-6 and IL-8. Thus, while moderate induction of IL-6 and 
IL-8 by IFNs might be required to efficiently activate the immune response, IFN pre-
treatment was well able to control the inflammation upon viral infection and 
prevent an exaggerated inflammatory response.  
Overall we have demonstrated that even low concentrations of IFN-λ1 and 
IFN-β are able to provoke a long-lasting antiviral state in airway epithelial cell 
monocultures as well as macrophage/epithelial cell co-cultures. Additionally we 
also showed that these IFNs are capable to prevent excessive inflammation in case 
of a viral infection. Taken together, these data indicate that administration of 
exogenous IFNs as a prophylactic treatment might be a therapeutic option e.g. in 
patients with chronic respiratory diseases, but also in the normal population to 
prevent common colds. Although the economic impact of the common cold is not 
very well understood, in the United States the common cold leads to 75–100 
million physician visits annually at a conservative cost estimate of $7.7 billion per 
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year. Thus, despite being relatively harmless, a more effective prevention of the 
common cold will have a significant impact on annual health cost.  
Effect of cigarette smoke extracts on antiviral response induced by exogenous IFN 
A variety of data exists indicating that cigarette smoke modulates the immune 
response to pathogens and that smokers have more frequent viral respiratory 
infections than non-smokers. [44,45]. Among COPD patients, most of them are 
either current or ex-smokers which is the most important single risk factor for the 
development of disease [46,47]. Similarly, among asthmatics about 25-30% are 
current smokers [48] and they seem to be significantly more susceptible to 
experience virus-induced exacerbations than non-smokers [49]. Different in vitro 
studies have shown that cigarette smoke impairs the antiviral response of epithelial 
cells of respiratory tract, in terms of production of IFNs [50-53]. This impaired 
production of IFNs following cigarette smoke exposure was the result of impaired 
expression or activation of different important molecules involved in the antiviral 
signaling [52-54]. Furthermore, it has also been shown that in cigarette smoke-
exposed fibroblasts the ability of exogenous IFNs to induce an antiviral state is also 
decreased [53,55]. Yet, whether cigarette smoke exerts the same effect in airway 
epithelial cells was not clear. Thus, once we had established the antiviral and 
inflammatory response of epithelial cells to exogenous IFNs, in chapter 4 we 
investigated whether cigarette smoke extracts (CSE) had an impact on the antiviral 
response provoked by exogenous IFN-β in epithelial cells. In line with previous 
studies we also found increased replication of virus in cells which were pre-treated 
with CSE, showing that cigarette smoke had indeed enhanced the susceptibility of 
the cells for viral infections. Furthermore, the ability of exogenous IFN-β to provide 
protection against viral infections in CSE-treated cells was also decreased. 
However, although the observed inhibition of viral replication by exogenous IFN-β 
in CSE-treated cells was slightly less than in control cells, this inhibition was still 
pronounced as compared to replication of virus in control cells or cells treated with 
CSE only. This implies that exogenous IFNs is still able to provide protection against 
viral infections even in smokers and indicates that also in smokers the epithelial 
lining of the airways, which is the primary site of viral entrance and replication in 
the respiratory tract, can be protected against viral infections by administration of 
exogenous IFNs. 
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Haemophilus influenzae promotes the cellular susceptibility for human 
Rhinovirus 
In order to prevent or reduce virus-induced exacerbations in chronic respiratory 
diseases, the availability of new appropriate therapies depends not only on 
development of new drugs, but also on a better understanding of the factors that 
affect the susceptibility of the host for viral infections. Among viruses, HRVs are the 
major inducers of acute exacerbations in COPD. Major group HRVs, which comprise 
about 90% of the known HRVs, use the Intercellular Adhesion Molecule-1 (ICAM-1) 
to attach to the cell surface and subsequently enter the cell. Thus factors which 
increase the cellular ICAM-1 expression will probably enhance the susceptibility of 
the cells for ensuing infections with major group HRVs. Non-typeable Haemophilus 
influenza (NTHI), a Gram-negative bacteria which is frequently isolated from COPD 
patients both during the clinically stable phase or an exacerbation phase [56-59], 
has been shown to enhance the expression of the ICAM-1 expression on epithelial 
cells [60,61]. Thus prior infections or colonization of the respiratory tract with NTHI 
may promote HRV infections and any possible exacerbations in patients with 
chronic respiratory diseases. 
After exploring the possibility to use exogenous IFNs to prevent virus 
induced exacerbations, in chapter 5 we tried to better understand the effect of 
NTHI treatment on the entrance and replication of HRV16, a member of the major 
group HRV, in bronchial epithelial cells. In line with a previous study we also found 
increased expression of ICAM-1 after NTHI treatment, which resulted in improved 
binding/entrance of HRV16 to the cells. Furthermore, replication of HRV16 was also 
significantly augmented in NTHI-pre-treated cells as compared to control cells. This 
indicates that NTHI pre-treatment increases the susceptibility of these cells for 
infection with major group HRVs. We also evaluated whether this effect is specific 
for major group HRVs or a general characteristic of NTHI-exposed cells. Therefore, 
experiments were repeated with a minor group HRV (HRV1B) and the unrelated 
respiratory syncytial virus (RSV). Results revealed that, although there was a slight 
increase in the replication of both HRV1B and RSV, this increase was markedly less 
than the increase observed when NTHI pre-treated cells were infected with HRV16. 
These findings suggest that the enhanced sensitivity of bronchial epithelial cells for 
major group HRVs is predominantly mediated through the enhanced expression of 
ICAM-1. Yet, as we also found an slight increase in replication of other non-major 
group HRV viruses, we cannot exclude that activation of epithelial cells non-
selectively increases their susceptibility towards viral infections. Nevertheless, since 
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many patients with chronic respiratory diseases are colonized by NTHI, our findings 
may to some extent explain the enhanced sensitivity of these patients for viral 
respiratory infections.  
Since airway inflammation is a salient aspect of acute COPD exacerbations 
[33], we next evaluated whether NTHI pre-treatment affected the inflammatory 
response of cells upon subsequent viral infection. Unexpectedly, neither HRV16 nor 
HRV1B induced the release of pro-inflammatory mediators by the epithelial cells, 
irrespective whether cells were first pretreated with NTHI or not. Alternatively, 
infection of epithelial cells with RSV resulted in the release of significant amount of 
IL-6 and IL-8. Moreover, infections of NTHI pre-treated cells showed a strong and 
synergistic increase in the production of these inflammatory mediators. This 
indicates that an initial infection or colonization with NTHI results in exaggerated 
inflammatory response upon subsequent viral infection. From a clinical viewpoint, 
these results imply that for patients with chronic respiratory diseases the chance to 
develop an acute exacerbation may become significantly enlarged once they have 
become colonized by NTH. 
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Conclusions and clinical perspectives 
 
Frequent exacerbations of chronic respiratory diseases have been shown to be 
closely associated with an accelerated decline in lung function. Also, they 
significantly enhance the chance for future morbidity and mortality. Currently 
there’s compelling evidence that a majority of these exacerbations are induced by 
respiratory viruses like rhinovirus, respiratory syncytial virus or influenza virus. 
Unfortunately, current antiviral therapies are usually inefficient to treat these 
infections. Moreover, there are indications that the pulmonary immune responses 
towards respiratory viruses are impaired in patients with chronic respiratory 
diseases. Inspired by this, in this thesis we studied whether the application of 
exogenous IFNs could be beneficial to prevent such respiratory infections. In 
various in vitro studies we demonstrated that low doses of both IFN-β and INF-λ1 
were well able to induce an antiviral state in airway epithelial cells. Importantly, 
this antiviral state was maintain for up to three days, suggesting that continuous 
administration of IFNs, which is usually accompanied by unwanted side effects, 
might not be necessary. Also, results indicated that IFN-λ1 might be better suited 
for future clinical application because 1) the expression of its receptor is less 
ubiquitous and more restricted to epithelial cells, and 2) the expression levels of 
the various ISG, which are the effector molecules in the IFN-induced antiviral 
response, are maintained at higher levels when cells were pretreated with IFN-λ1. 
Moreover, we demonstrated that that the application of IFNs itself induced only a 
moderate inflammatory response in a more complex model system consisting of 
co-cultured epithelial cells and macrophages. More importantly, however, IFN 
pretreatment dramatically reduced the inflammatory reaction in co-cultured cells 
which were subsequently infected with RSV, providing further evidence that 
prophylactic IFNs treatment not only prevents viral replication, but also controls 
excessive inflammation in the airways.  
As already mentioned, patients with chronic respiratory diseases are more 
susceptible for viral infections because of an impaired pulmonary immune system. 
In this thesis we also revealed an alternative mechanism, which may explain why 
these patients are more susceptible for viral infections. Although it has been 
demonstrated earlier that viral infections increase the susceptibility for bacterial 
infections, the reverse has been addressed less extensively. Here we demonstrated 
that non-typeable Haemophilus influenzae significantly increased the susceptibility 
of epithelial cells for major group rhinoviruses, probably by enhancing the 
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expression of ICAM-1, which is used by this specific group of rhinoviruses for 
attachment to the cell surface. Since the airways of the majority of patients with 
chronic respiratory diseases are colonized with NTHI, this may partially explain why 
these patients are so susceptible for this specific group of viruses. 
Summarizing, the data in this thesis strongly suggest that both type I and 
III IFNs have potential as prophylactic agents to prevent viral infections of the 
respiratory tract (Figure 1). 
 
 
Figure-1. Schematic representation of antiviral defense of airway epithelium in different conditions: 
Upon viral infections of healthy airway epithelium, cells start producing and releasing IFNs which then 
bind to their specific receptors in an auto-or paracrine way and protect the infected as well as non-
infected cells (A). However, in chronic respiratory diseases like asthma and COPD, antiviral response of 
airway epithelium becomes impaired. As a result upon viral infections cells produce insufficient amounts 
of IFNs which do not efficiently protect them against viral infection (B). Yet prophylactic treatment of 
these cells with exogenous IFNs induces a strong antiviral state, which protects them from subsequent 
viral infections (C). 
 
Especially in patients with chronic respiratory diseases like asthma or COPD, 
prophylactic treatment with exogenous IFNs could be beneficial to prevent virus-
induced exacerbations. However, the major limitation of the studies presented in 
this thesis is the fact that only in vitro studies have been performed. As already 
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eluded in chapter 3, the pulmonary immune systems consists of various different 
cells, which all collaborate in an intense network to combat e.g. invading 
pathogens. In such a network, responses to exogenous IFNs might be different or 
less efficient. Therefore, additional clinical studies are mandatory. Earlier, clinical 
trials examining the effects of type I IFN revealed beneficial effects in 
corticosteroid-resistant asthmatics by shifting the Th1/Th2 balance [27], or as a 
prophylactic antiviral agent in healthy individuals [62-64]. However, in most of 
these studies adverse side effects were noticed including flu-like symptoms, dry 
pharynx and/or nasal erosion/bleeding. It may be speculated that these side effects 
result in particularly from the daily administration of IFN. Therefore, a prerequisite 
for future clinical use will be a sustained antiviral state of the epithelial cells the 
after application of a single (preferably low) dose as frequent administrations of 
high doses may cause the aforementioned side effects. And although we have 
demonstrated that both IFN-β as IFN-λ indeed meet these criteria in an in vitro 
model, their efficacy needs to be tested in vivo before being suitable for clinical 
applications. Interestingly, Djukanovic et al. recently reported that treatment with 
inhaled IFN-β once every 3 days during a period of 15 days significantly attenuated 
the adverse effects of the common cold in difficult to treat asthma patients [65]. 
These data strongly suggest that exogenous IFN-β might indeed be efficacious to 
treat or even prevent acute exacerbations in certain patients. Alternatively, 
although clinical trials of type-III IFNs to treat chronic hepatitis patients are in 
currently progress, to our knowledge in chronic respiratory patients no studies with 
type-III IFNs are currently being conducted. Nevertheless, because of its long-
lasting antiviral effect and due to the restricted expression of its receptors, IFN-λ1 
might even be a better choice than IFN-β. Therefore, clinical studies assessing the 
efficacy of type III IFNs to treat or prevent virus-related acute exacerbations in 
patients with chronic respiratory diseases are eagerly awaited. 
Over the past decade, there has been a continuous discussion regarding 
the efficacy of long term antibiotic treatment for the prevention of acute 
exacerbations in chronic respiratory patients. And although the chronic use of 
antibiotic is usually not recommended because of lack of efficacy and the risk for 
antibiotic resistance [66], recent data have shown beneficial effects of long-term 
fluoroquinolone or macrolide use [67-70]. It has been speculated that these 
positive results should be attributed to the interruption of the vicious circle of 
(chronic) infection-inflammation, which will ultimately reduce the susceptible of 
patients for infections by strengthening the lung defense systems. Moreover, the 
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data presented in chapter 5 suggest that bacterial colonization may result in 
enhance the susceptibility for viral infections and result in excessive inflammation 
once the colonized patients become infected with certain viruses. Thus, these 
findings also suggest that antibiotic treatment in particular of colonized patients 
may be helpful in the prevention of virus-induced acute exacerbations in these 
patients. Yet, future in vivo experiments as well as clinical trials are needed to 
prove these concepts. 
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Samenvatting 
 
Onder normale omstandigheden inhaleert een volwassen menselijke long zo’n 
11.000 liter lucht per dag. Naast deze normale lucht worden er ook potentieel 
toxische stoffen en micro-organismen, zoals bacteriën, virussen, schimmels of 
parasieten, ingeademd. In het merendeel van de gevallen is het immuunsysteem 
van de longen in staat om deze ingeademde stoffen en micro-organismen op te 
ruimen en daarmee de longen te beschermen tegen infecties en hun normale 
functie te handhaven. Echter, wanneer deze beschermende werking vermindert, 
kunnen uiteindelijk longziekten ontstaan. Deze kunnen variëren van acuut (vaak 
hevig maar kortdurend) tot langdurig en onomkeerbaar. 
Hoewel de prevalentie van luchtweginfecties als gevolg van hygiëne 
maatregelen en de ontwikkeling van nieuwe geneesmiddelen en vaccins drastisch 
verminderd is, zijn dergelijke infecties nog steeds een grote belasting voor de 
gemeenschap in termen van ziekte, overlijden en gezondheidskosten. Veelal 
worden deze infecties veroorzaakt door virussen. De infecties zijn vaak onschuldig 
– denk hierbij aan een normale verkoudheid – en duren vaak niet langer dan een 
aantal dagen. Echter, in patiënten met chronische longziekten zoals astma en 
COPD, waarbij de werking van het immuunsysteem vaak verminderd is, kunnen 
dergelijke infecties leiden tot een ernstige verslechtering van de conditie van de 
patiënt (een zogenaamde “acute exacerbatie”) en zelfs levensbedreigend zijn. 
Helaas blijken de momenteel beschikbare antivirale middelen 
onvoldoende geschikt om deze door virale infecties veroorzaakte acute 
exacerbaties te voorkomen of te behandelen. Daarom is het van groot belang dat 
er op korte termijn nieuwe en betere antivirale therapieën ontwikkeld worden. Een 
mogelijke strategie hierbij zou kunnen zijn het bestuderen van afwijkingen in de 
afweerreactie tegen virussen en het mogelijk herstellen van deze afwijkingen. Ook 
kan het nuttig zijn om te bestuderen welke factoren verantwoordelijk zijn voor de 
verhoogde gevoeligheid van patiënten met chronische luchtwegklachten voor 
infecties van de luchtwegen. Met deze kennis zal het eventueel mogelijk zijn om tot 
nieuwe efficiënte therapieën te komen zodat patiënten met chronische luchtweg 
klachten beter beschermd zijn tegen respiratoire infecties en de eventueel daaruit 
voortvloeiende acute exacerbaties.  
 
Wanneer cellen geïnfecteerd raken zullen ze reageren via het produceren 
van diverse stoffen om de infectie te bestrijden. Tot deze stoffen behoren de 
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zogenaamde interferonen, welke een sterk antivirale werking hebben. Wanneer 
deze interferonen geproduceerd worden, zullen ze de cellen waardoor ze 
geproduceerd worden stimuleren maar ook cellen in de directe nabijheid. Op deze 
wijze worden gestimuleerde cellen in een antivirale staat gebracht, waardoor ze 
beschermd zijn tegen mogelijke infecties. Echter, in patiënten met astma en COPD 
lijkt dit systeem verstoord en worden er tijdens infecties beduidend minder 
interferonen geproduceerd door de cellen in de luchtwegen. Daarnaast hebben 
virussen bepaalde strategieën ontwikkeld om aan het afweersysteem te 
ontsnappen; deze strategieën zijn meestal gebaseerd op het onderdrukken van de 
werking van deze interferonen. Ondanks het feit dat cellen minder interferonen 
produceren en/of dat de productie van interferonen door virussen onderdrukt 
wordt, blijken de cellen wel nog in staat te zijn op interferonen te reageren. Op 
basis van deze bevindingen hebben we in dit proefschrift onderzocht in hoeverre 
het mogelijk is om cellen middels van buitenaf toegevoegde (“exogeen”) 
interferonen te beschermen tegen toekomstige virale infecties en mogelijk tegen 
de vaak daarmee gepaarde acute exacerbaties. Ook hebben we onderzocht in 
hoeverre bacteriële infecties het effect van virale infecties kunnen versterken.  
 
De verschillende typen interferonen (IFN) kunnen worden onderverdeeld in 3 
groepen: 
i) Type I interferonen, waartoe IFN-α en IFN-β behoren 
ii) Type II interferon, welke groep uitsluitend uit INF-γ bestaat 
iii) Type II interferonen. Deze groep is het meest recent ontdekt en 
bestaat uit IFN-λ1 λ-2 en λ-3 
Van deze 3 groepen zijn de typen I en III de meest belangrijke wanneer het 
gaat om de antivirale afweer. Beide typen zijn instaat om de cellulaire productie 
van een groot aantal stoffen met antivirale werking (de zgn. “interferon-stimulated 
genes”(ISG)) aan te zetten. Echter, ze doen dit via stimulatie van verschillende 
receptoren op de cel. Hierbij is het van belang dat de receptoren voor type I IFN op 
vrijwel alle cellen voorkomen, terwijl de receptoren voor type III IFN vrijwel 
uitsluitend op epitheel cellen voorkomen. Aangezien deze epitheel cellen in de 
luchtwegen de eerste cellen zijn die door virussen worden geïnfecteerd, is het 
waarschijnlijk dat de type III IFN in de luchtwegen belangrijker zijn voor de 
antivirale afweer dan de type I IFNs. In eerdere experimenten in ons lab hebben we 
reeds aangetoond dat epitheel cellen na blootstelling aan IFN-β langdurig 
beschermend waren tegen daaropvolgende virale infecties. In dit proefschrift 
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hebben we onderzocht in hoeverre IFN-λ1 ook in staat is om diverse cellen te 
beschermen tegen virale infecties. De resultaten van deze studie zoals beschreven 
in hoofdstuk 2 toonden aan dat een eenmalige voorbehandeling met IFN-λ1 zorgde 
voor een langdurige bescherming welke minimaal gelijkwaardig was aan het effect 
van IFN-β. Ook bleek dat de expressie van diverse ISGs na stimulatie met IFN-λ1 
langdurig verhoogd bleef, terwijl de door IFN-β geïnduceerde expressie sterk afnam 
na verloop van tijd. Dit suggereert dat de door IFN-λ1 veroorzaakte antivirale 
conditie mogelijk langer zal aanhouden dan de door IFN-β geïnduceerde staat. 
Samenvattend kunnen we zeggen dat IFN-λ1, net als IFN-β, profylactische en 
beschermende werking heeft in het voorkomen van virale infecties en dat het 
effect van IFN-λ1 mogelijk langduriger is dan het effect van IFN-β. 
 
Hoewel acute exacerbaties veroorzaakt worden door diverse prikkels zoals 
allergenen, sigarettenrook of luchtweginfecties, blijken ontstekingsreacties in 
vrijwel alle gevallen een rol te spelen. Nu hebben we eerder laten zien dat IFNs 
beschermend werken tegen virale infecties, maar het was onduidelijk of IFNs zelf 
ook tot een ontstekingsreactie zouden kunnen leiden. Ook zou de interactie tussen 
cellen van belang kunnen zijn omdat de afweer in de longen het gevolg is van een 
direct samenspel tussen diverse celtypen. Als gevolg hiervan zou het uiteindelijke 
therapeutische effect van bijvoorbeeld IFNs in de menselijke long anders kunnen 
zijn dan zoals eerder bestudeerd in een celkweek met één enkel celtype (bv 
epitheel cellen). Om dit te bestuderen hebben we in hoofdstuk 3 gebruik gemaakt 
van een zogenaamde co-cultuur, waarbij 2 celtypen, die beiden betrokken zijn bij 
de afweer in de luchtwegen (macrofagen en epitheel cellen), gezamenlijk werden 
gekweekt en vervolgens werden blootgesteld aan zowel IFN-λ1 als IFN-β. De 
resultaten toonden aan dat blootstelling aan zowel IFN-λ1 als IFN-β zorgde voor 
een lichte ontstekingsreactie. Echter, wanneer de blootstelde cellen vervolgens ook 
geïnfecteerd werden, bleek dat niet alleen de infectie voorkomen kon worden 
maar dat de ontstekingsreactie ook sterk verminderd was in vergelijking met de 
ontstekingsreactie die veroorzaakt werd door het virus in onbehandelde cellen. Dit 
leidde tot de conclusie dat blootstelling aan IFN weliswaar zorgde voor een geringe 
ontstekingsreactie, maar dat deze ontstekingsreactie mogelijk noodzakelijk is om 
een daaropvolgende virale infectie beter te bestrijden en de door het virus 
veroorzaakte ontsteking binnen de perken te houden. 
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Helaas blijkt een deel van alle patiënten met astma en COPD niet in staat 
te zijn om te stoppen met roken. Nu blijkt roken de gevoeligheid voor virale 
infecties van de luchtwegen sterk te verhogen, waarschijnlijk via het aantasten van 
het afweer systeem in de longen. Vooral de productie van IFN lijkt aangetast te 
worden door de toxische bestanddelen in sigarettenrook. Of sigarettenrook ook de 
reactie op exogeen IFN kan beïnvloeden was echter onbekend. Dit is bestudeerd in 
hoofdstuk 4. In de in dit hoofdstuk beschreven experimenten werden epitheel 
cellen blootgesteld aan een extract van sigarettenrook en werd vervolgens gekeken 
of de antivirale werking van exogeen IFN-β hierdoor werd aangetast. Uit de 
resultaten bleek dat de blootstelling aan dit extract de antivirale werking van IFN-β 
inderdaad enigszins verminderde. Gelukkig bleek het overgebleven effect nog ruim 
voldoende om epitheel cellen te beschermen tegen een daaropvolgende virale 
infectie. Deze resultaten geven aan dat ook in rokers het beschermende effect van 
IFN-β gehandhaafd blijft. 
 
Nadat we in de hoofdstukken 2-4 de mogelijke toepasbaarheid van 
exogene IFNs als beschermende therapie tegen virale infecties hebben onderzocht, 
is in hoofdstuk 5 getracht een beter inzicht te krijgen in de rol die bacteriële 
infecties kunnen spelen bij een verhoogde gevoeligheid voor virale infecties en/of 
acute exacerbaties. In het bijzonder is gekeken naar de rol van Haemophilus 
influenzae (HI), een bacterie die vaak aangetroffen wordt in de lagere luchtwegen 
zowel tijdens een exacerbatie als tijdens de stabiele fase bij COPD patiënten, en 
diverse virussen die vaker in COPD patiënten gevonden worden tijdens acute 
exacerbaties. Onze data toonden aan dat aan HI blootgestelde epitheel cellen 
vooral gevoeliger waren voor infecties met een bepaald type rhinovirus (HRV16), 
een typisch verkoudsheidsvirus, en minder voor infecties met ander type rhinovirus 
(HRV1B) of met RSV. Dit verschil is waarschijnlijk te verklaren door de bevinding dat 
blootstelling aan HI zorgde voor een versterkte expressie van een receptor die 
specifiek door HRV16, maar niet door HRV1B of RSV gebruikt wordt om een cel 
binnen te dringen. Daarnaast bleek de ontstekingsreactie versterkt in HI 
blootgestelde cellen na virale infecties. Hieruit kan geconcludeerd worden dat 
(chronische) infecties met Haemophilus influenzae in combinatie met een virale 
infectie zorgen voor een verhevigde ontstekingsreactie en mogelijk voor een 
verhoogd risico op acute exacerbaties. 
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Samenvattend kunnen we zeggen dat de resultaten zoals beschreven in dit 
proefschrift sterke aanwijzingen bieden voor: 
- een rol voor zowel type I als type II interferonen in het voorkomen van 
zowel de virale infectie sec als de daarmee gepaard gaande 
ontstekingsreactie 
- een rol voor antibiotica in COPD patiënten met chronische bacteriële 
infecties (in het bijzonder met Haemophilus influenzae) van de luchtwegen 
ter voorkoming van excessieve virale infecties en ontstekingsreacties en 
de daarmee vaak gepaard gaande acute exacerbaties. 
Wel dient opgemerkt te worden dat de in dit proefschrift beschreven 
experimenten uitgevoerd zijn in modellen gebaseerd op geïsoleerde cellen. In 
hoeverre de voorgestelde concepten daadwerkelijk toepasbaar zullen zijn in de 
kliniek zullen toekomstige experimenten en mogelijke klinische studies moete.  
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AEs Acute Exacerbations 
AP1 Activator Protein 1 
ARIs Acute Respiratory tract Infections 
ASL Airway Surface Liquid 
COPD Chronic Obstructive Pulmonary Disease 
CPE Cytopathogenic Effect 
CRD Chronic Respiratory Diseases 
CSE Cigarette Smoke Extracts 
ELISA Enzyme-linked immunosorbent assay 
FCS Fetal Calf Serum 
Hi Heat inactivated 
HRV Human Rhinovirus 
ICAM-1 Intercellular Adhesion Molecule-1 
IFN Interferon 
IFN-α Interferon-alpha 
IFN-β Interferon-beta 
IFN-γ Interferon-gamma 
IFN-λ Interferon-lambda 
IL Interleukin 
IL-1RA Interleukin-1 Receptor Antagonist 
IRF Interferon regulatory Factor 
ISG Interferon Stimulated Genes 
LDL Low Density Lipoprotein 
LRTIs Lower Respiratory tract Infections 
MDA5 Melanoma Differentiated Associated gene 5 
MOI Multiplicity Of Infection 
MTT Thiazolyl Blue Tetrazolium Bromide 
MX1 Myxovirus Resistance 1 
NFκB Nuclear Factor kappa B 
NTHI Non-typeable Haemophilus influenzae 
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PBEC Primary Bronchial Epithelial Cells 
PBMC Peripheral Blood Mononuclear Cells 
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RSV Respiratory Syncytial Virus 
SEM Standard Error of the Mean 
TCID50 50% Tissue Culture Infectivity Dose 
TLR Toll Like Receptors 
URTs Upper Respiratory tract Infection 
WHO World Health Organization 
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